This page is part of the International Patient Summary Implementation Guide (v0.3.0: STU 1 (FHIR R4) Ballot 1) based on FHIR R4. The current version which supercedes this version is 1.1.0. For a full list of available versions, see the Directory of published versions 
| Defining URL: | http://hl7.org/fhir/uv/ips/ValueSet/pathology-and-vital-signs-observations |
| Version: | 0.3.0 |
| Name: | IPSPathResultsObservation |
| Definition: | Note: This definition is only partially implemented and the current value set expansion contains more than the expected set of codes, as the required regex filters for the LOINC code system are not currently supported by the terminology service. |
| Publisher: | HL7 International |
| Source Resource: | XML / JSON / Turtle |
IPS Results Observation Pathology
Value Set Definition:
LOINC { { COMPONENT not ( containing the word "panel" OR starting with "can pronounce" ) CLASS in {CYTO, HEM/BC, HL7.CYTOGEN, HL7.GENETICS, MOLPATH, MOLPATH.*, PATH} STATUS in {ACTIVE} CLASSTYPE in {1} ORDER_OBS in
{Observation, Both} } UNION { COMPONENT not ( containing the word "panel" OR starting with "can pronounce" ) STATUS in {ACTIVE} CLASSTYPE in {2} ORDER_OBS in {Observation, Both} SYSTEM = ^Patient }}
Note: This definition is only partially implemented and the current value set expansion contains more than the expected set of codes, as the required regex filters for the LOINC code system are not currently supported by the terminology service.
This value set includes codes from the following code systems:
- Include codes from
http://loinc.orgwhere STATUS = ACTIVE andhttp://loinc.orgwhere CLASSTYPE = 1 - Include codes from
http://loinc.orgwhere STATUS = ACTIVE andhttp://loinc.orgwhere CLASSTYPE = 2 andhttp://loinc.orgwhere SYSTEM = ^Patient
Expansion
This value set contains 2000 concepts
All codes from system http://loinc.org
| Code | Display |
| 1-8 | Acyclovir [Susceptibility] |
| 10-9 | Amdinocillin [Susceptibility] by Serum bactericidal titer |
| 100-8 | Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 1000-9 | DBG Ab [Presence] in Serum or Plasma from Blood product unit |
| 1001-7 | DBG Ab [Presence] in Serum or Plasma from Donor |
| 1002-5 | DBG Ab [Presence] in Serum or Plasma |
| 1003-3 | Indirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma |
| 1004-1 | Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells |
| 1005-8 | Indirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma |
| 1006-6 | Direct antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells |
| 1007-4 | Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells |
| 1008-2 | Indirect antiglobulin test.poly specific reagent [Presence] in Serum or Plasma |
| 101-6 | Cefoperazone [Susceptibility] by Disk diffusion (KB) |
| 1010-8 | E sup(w) Ab [Presence] in Serum or Plasma from Blood product unit |
| 1011-6 | E sup(w) Ab [Presence] in Serum or Plasma from Donor |
| 1012-4 | E sup(w) Ab [Presence] in Serum or Plasma |
| 1013-2 | E sup(w) Ag [Presence] on Red Blood Cells from Blood product unit |
| 1014-0 | E sup(w) Ag [Presence] on Red Blood Cells from Donor |
| 1015-7 | E sup(w) Ag [Presence] on Red Blood Cells |
| 1016-5 | E Ab [Presence] in Serum or Plasma from Blood product unit |
| 1017-3 | E Ab [Presence] in Serum or Plasma from Donor |
| 1018-1 | E Ab [Presence] in Serum or Plasma |
| 1019-9 | E Ag [Presence] on Red Blood Cells from Blood product unit |
| 102-4 | Cefoperazone [Susceptibility] by Serum bactericidal titer |
| 1020-7 | E Ag [Presence] on Red Blood Cells from Donor |
| 1021-5 | E Ag [Presence] on Red Blood Cells |
| 1022-3 | Fy sup(a) Ab [Presence] in Serum or Plasma from Blood product unit |
| 10226-9 | Oxygen content in Intravascular space |
| 1023-1 | Fy sup(a) Ab [Presence] in Serum or Plasma from Donor |
| 10232-7 | Oxygen content in Aorta root |
| 10233-5 | Oxygen content in Left atrium |
| 10234-3 | Oxygen content in Right atrium |
| 10235-0 | Oxygen content in High right atrium |
| 10236-8 | Oxygen content in Low right atrium |
| 10237-6 | Oxygen content in Mid right atrium |
| 10238-4 | Oxygen content in Left ventricle |
| 10239-2 | Oxygen content in Right ventricular outflow tract |
| 1024-9 | Fy sup(a) Ab [Presence] in Serum or Plasma |
| 10240-0 | Oxygen content in Right ventricle |
| 10241-8 | Oxygen content in Coronary sinus |
| 10242-6 | Oxygen content in Ductus arteriosus |
| 10243-4 | Oxygen content in Inferior vena cava |
| 10244-2 | Oxygen content in Left pulmonary artery |
| 10245-9 | Oxygen content in Main pulmonary artery |
| 10246-7 | Oxygen content in Right pulmonary artery |
| 10247-5 | Oxygen content in Pulmonary wedge |
| 10248-3 | Oxygen content in Superior vena cava |
| 1025-6 | Fy sup(a) Ag [Presence] on Red Blood Cells from Blood product unit |
| 1026-4 | Fy sup(a) Ag [Presence] on Red Blood Cells from Donor |
| 1027-2 | Fy sup(a) Ag [Presence] on Red Blood Cells |
| 1028-0 | Fy sup(b) Ab [Presence] in Serum or Plasma from Blood product unit |
| 1029-8 | Fy sup(b) Ab [Presence] in Serum or Plasma from Donor |
| 103-2 | Ceforanide [Susceptibility] by Minimum lethal concentration (MLC) |
| 1030-6 | Fy sup(b) Ab [Presence] in Serum or Plasma |
| 1031-4 | Fy sup(b) Ag [Presence] on Red Blood Cells from Blood product unit |
| 1032-2 | Fy sup(b) Ag [Presence] on Red Blood Cells from Donor |
| 10327-5 | Eosinophils/100 leukocytes in Sputum by Manual count |
| 10328-3 | Lymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count |
| 10329-1 | Monocytes/100 leukocytes in Cerebral spinal fluid by Manual count |
| 1033-0 | Fy sup(b) Ag [Presence] on Red Blood Cells |
| 10330-9 | Monocytes/100 leukocytes in Body fluid by Manual count |
| 10331-7 | Rh [Type] in Blood |
| 10332-5 | Cortisol [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM |
| 10333-3 | Appearance of Cerebral spinal fluid |
| 10334-1 | Cancer Ag 125 [Units/volume] in Serum or Plasma |
| 10335-8 | Color of Cerebral spinal fluid |
| 10336-6 | Gonadotropin peptide [Mass/volume] in Urine |
| 10337-4 | Procollagen type I [Mass/volume] in Serum |
| 10338-2 | Barbiturates [Mass/volume] in Serum or Plasma |
| 10339-0 | Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma |
| 1034-8 | Fetal cell screen [Interpretation] in Blood |
| 10340-8 | Molindone [Mass/volume] in Serum or Plasma |
| 10341-6 | Norpropoxyphene [Mass/volume] in Serum or Plasma |
| 10342-4 | Sulfamethoxazole [Mass/volume] in Serum or Plasma |
| 10343-2 | Temazepam [Mass/volume] in Serum or Plasma |
| 10344-0 | Tranylcypromine [Mass/volume] in Serum or Plasma |
| 10345-7 | Trihexyphenidyl [Mass/volume] in Urine |
| 10346-5 | Hemoglobin A [Units/volume] in Blood by Electrophoresis |
| 10347-3 | Babesia microti identified in Blood by Light microscopy |
| 10348-1 | Bordetella parapertussis Ab [Presence] in Serum |
| 10349-9 | Brucella sp Ab [Units/volume] in Serum |
| 1035-5 | Fresh frozen plasma given [Volume] |
| 10350-7 | Herpes simplex virus IgM Ab [Titer] in Serum by Immunoassay |
| 10351-5 | HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification |
| 10352-3 | Bacteria identified in Genital specimen by Aerobe culture |
| 10353-1 | Bacteria identified in Nose by Aerobe culture |
| 10354-9 | Bacteria identified in Urethra by Culture |
| 10355-6 | Microscopic observation [Identifier] in Bone marrow by Wright Giemsa stain |
| 10357-2 | Microscopic observation [Identifier] in Wound by Gram stain |
| 10358-0 | Teichoate Ab [Titer] in Serum by Immune diffusion (ID) |
| 10359-8 | Asialoganglioside GM1 IgM Ab [Titer] in Serum |
| 1036-3 | G Ab [Presence] in Serum or Plasma from Blood product unit |
| 10360-6 | DNA single strand IgG Ab [Units/volume] in Serum |
| 10361-4 | DNA single strand IgM Ab [Units/volume] in Serum |
| 10362-2 | Endomysium IgA Ab [Presence] in Serum |
| 10363-0 | Barbiturates [Presence] in Unspecified specimen |
| 10364-8 | Cotinine [Mass/mass] in Hair |
| 10365-5 | Cotinine [Mass/volume] in Serum or Plasma |
| 10366-3 | Cotinine [Mass/volume] in Urine |
| 10367-1 | Ethanol [Mass/volume] in Gastric fluid |
| 10368-9 | Lead [Mass/volume] in Capillary blood |
| 10369-7 | Opiates [Mass/mass] in Hair |
| 1037-1 | G Ab [Presence] in Serum or Plasma from Donor |
| 10370-5 | Phencyclidine [Mass/mass] in Hair |
| 10371-3 | Bite cells [Presence] in Blood by Light microscopy |
| 10372-1 | Blister cells [Presence] in Blood by Light microscopy |
| 10373-9 | Fragments [Presence] in Blood by Light microscopy |
| 10374-7 | Helmet cells [Presence] in Blood by Light microscopy |
| 10375-4 | Irregularly contracted cells [Presence] in Blood by Light microscopy |
| 10376-2 | Oval macrocytes [Presence] in Blood by Light microscopy |
| 10377-0 | Pencil cells [Presence] in Blood by Light microscopy |
| 10378-8 | Polychromasia [Presence] in Blood by Light microscopy |
| 10379-6 | Erythrocytes.dual population [Presence] in Blood by Light microscopy |
| 1038-9 | G Ab [Presence] in Serum or Plasma |
| 10380-4 | Stomatocytes [Presence] in Blood by Light microscopy |
| 10381-2 | Target cells [Presence] in Blood by Light microscopy |
| 10385-3 | Albumin concentration given |
| 10386-1 | Albumin given [Volume] |
| 10387-9 | Autologous erythrocytes given [Volume] |
| 10388-7 | Autologous whole blood given [Volume] |
| 10389-5 | Blood product.other [Type] |
| 1039-7 | G Ag [Presence] on Red Blood Cells from Blood product unit |
| 10390-3 | Blood product special preparation [Type] |
| 10391-1 | Cytomegalovirus immune globulin given [Volume] |
| 10392-9 | Cryoprecipitate given [Volume] |
| 10393-7 | Factor IX given [Type] |
| 10394-5 | Factor IX given [Volume] |
| 10395-2 | Factor VIII given [Type] |
| 10396-0 | Factor VIII given [Volume] |
| 10397-8 | Hepatitis B immune globulin given [Volume] |
| 10398-6 | I Ag [Presence] on Red Blood Cells from Blood product unit |
| 10399-4 | I Ag [Presence] on Red Blood Cells from Donor |
| 104-0 | Ceforanide [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 1040-5 | G Ag [Presence] on Red Blood Cells from Donor |
| 10400-0 | I Ag [Presence] on Red Blood Cells |
| 10401-8 | Immune serum globulin given [Type] |
| 10402-6 | Immune serum globulin given [Volume] |
| 10403-4 | Inject immune serum globulin [Volume] |
| 10404-2 | Inject Rh immune globulin [Volume] |
| 10405-9 | Inject varicella zoster virus immune globulin [Volume] |
| 10406-7 | little i Ag [Presence] on Red Blood Cells from Blood product unit |
| 10407-5 | little i Ag [Presence] on Red Blood Cells from Donor |
| 10408-3 | little i Ag [Presence] on Red Blood Cells |
| 10409-1 | Pentaspan given [Volume] |
| 1041-3 | G Ag [Presence] on Red Blood Cells |
| 10410-9 | Plasma given [Type] |
| 10411-7 | Plasma given [Volume] |
| 10412-5 | Platelets given [Type] |
| 10413-3 | Rh immune globulin given [Volume] |
| 10414-1 | Transfuse albumin [Volume] |
| 10415-8 | Transfuse blood exchange transfusion [Volume] |
| 10416-6 | Transfuse blood product other [Volume] |
| 10417-4 | Transfuse cryoprecipitate [Volume] |
| 10418-2 | Transfuse factor IX [Volume] |
| 10419-0 | Transfuse factor VIII [Volume] |
| 1042-1 | H Ab [Presence] in Serum or Plasma from Blood product unit |
| 10420-8 | Transfuse immune serum globulin [Volume] |
| 10421-6 | Transfuse Pentaspan [Volume] |
| 10422-4 | Transfuse plasma [Volume] |
| 10423-2 | Transfuse platelets [Volume] |
| 10424-0 | Transfuse erythrocytes [Volume] |
| 10425-7 | Transfuse Rh immune globulin [Volume] |
| 10426-5 | Transfuse whole blood [Volume] |
| 10427-3 | Transfuse whole blood autologous [Volume] |
| 10428-1 | Varicella zoster virus immune globulin given [Volume] |
| 10429-9 | AE 1 Ag [Presence] in Tissue by Immune stain |
| 1043-9 | H Ab [Presence] in Serum or Plasma from Donor |
| 10430-7 | AE 3 Ag [Presence] in Tissue by Immune stain |
| 10431-5 | B-cell Ag [Presence] in Tissue by Immune stain |
| 10432-3 | CD30 Ag [Presence] in Tissue by Immune stain |
| 10433-1 | BR-2 Ag [Presence] in Tissue by Immune stain |
| 10434-9 | Complement C3 Ag [Presence] in Tissue by Immune stain |
| 10435-6 | C5B-9 Ag [Presence] in Tissue by Immune stain |
| 10436-4 | CD15 Ag [Presence] in Tissue by Immune stain |
| 10437-2 | CD16 Ag [Presence] in Tissue by Immune stain |
| 10438-0 | CD20 Ag [Presence] in Tissue by Immune stain |
| 10439-8 | CD3 Ag [Presence] in Tissue by Immune stain |
| 1044-7 | H Ab [Presence] in Serum |
| 10441-4 | CD34 Ag [Presence] in Tissue by Immune stain |
| 10442-2 | CD56 Ag [Presence] in Tissue by Immune stain |
| 10443-0 | CD43 T-cell monocyte+myeloid cell Ag [Presence] in Tissue by Immune stain |
| 10444-8 | CD57 Ag [Presence] in Tissue by Immune stain |
| 10445-5 | CD11c Ag [Presence] in Tissue by Immune stain |
| 10446-3 | Leukocyte common Ag [Presence] in Tissue by Immune stain |
| 10447-1 | M-5 Ag [Presence] in Tissue by Immune stain |
| 10448-9 | T-cell Ag [Presence] in Tissue by Immune stain |
| 10449-7 | Glucose [Mass/volume] in Serum or Plasma --1 hour post meal |
| 10450-5 | Glucose [Mass/volume] in Serum or Plasma --10 hours fasting |
| 10451-3 | Proinsulin [Moles/volume] in Serum or Plasma --12 hours fasting |
| 10452-1 | Xylose [Mass/volume] in Serum or Plasma --1 hour post 25 g xylose PO |
| 10453-9 | Xylose [Mass/volume] in Serum or Plasma --1 hour post dose xylose PO |
| 10454-7 | Xylose [Mass/volume] in Serum or Plasma --2 hours post 25 g xylose PO |
| 10455-4 | Xylose [Mass/volume] in Serum or Plasma --30 minutes post 25 g xylose PO |
| 10456-2 | Xylose [Mass/volume] in Serum or Plasma --6 hours fasting |
| 10457-0 | Actin Ag [Presence] in Tissue by Immune stain |
| 10458-8 | Alkaline phosphatase.placental Ag [Presence] in Tissue by Immune stain |
| 10459-6 | Alpha-1-Fetoprotein Ag [Presence] in Tissue by Immune stain |
| 10460-4 | Lactalbumin alpha Ag [Presence] in Tissue by Immune stain |
| 10461-2 | Alpha-1-Antichymotrypsin Ag [Presence] in Tissue by Immune stain |
| 10462-0 | Alpha 1 antitrypsin Ag [Presence] in Tissue by Immune stain |
| 10463-8 | Amyloid A component Ag [Presence] in Tissue by Immune stain |
| 10464-6 | Amyloid P component Ag [Presence] in Tissue by Immune stain |
| 10465-3 | Amyloid.prealbumin Ag [Presence] in Tissue by Immune stain |
| 10466-1 | Anion gap 3 in Serum or Plasma |
| 10467-9 | Beta-2-Microglobulin amyloid Ag [Presence] in Tissue by Immune stain |
| 10468-7 | Calcitonin Ag [Presence] in Tissue by Immune stain |
| 10469-5 | Carcinoembryonic Ag [Presence] in Tissue by Immune stain |
| 10470-3 | Choriogonadotropin Ag [Presence] in Tissue by Immune stain |
| 10471-1 | Chromogranin A Ag [Presence] in Tissue by Immune stain |
| 10472-9 | Chromogranin Ag [Presence] in Tissue by Immune stain |
| 10473-7 | Chymotrypsin Ag [Presence] in Tissue by Immune stain |
| 10474-5 | Collagen type 4 Ag [Presence] in Tissue by Immune stain |
| 10475-2 | Corticotropin Ag [Presence] in Tissue by Immune stain |
| 10476-0 | Desmin Ag [Presence] in Tissue by Immune stain |
| 10477-8 | Enolase.neuron specific Ag [Presence] in Tissue by Immune stain |
| 10478-6 | Eosinophil major basic protein Ag [Presence] in Tissue by Immune stain |
| 10479-4 | CD227 Ag [Presence] in Tissue by Immune stain |
| 10480-2 | Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain |
| 10481-0 | Follitropin.alpha subunit Ag [Presence] in Tissue by Immune stain |
| 10482-8 | Follitropin.beta subunit Ag [Presence] in Tissue by Immune stain |
| 10483-6 | Gastrin Ag [Presence] in Tissue by Immune stain |
| 10484-4 | Glial fibrillary acidic protein Ag [Presence] in Tissue by Immune stain |
| 10485-1 | Glucagon Ag [Presence] in Tissue by Immune stain |
| 10486-9 | Hemoglobin Ag [Presence] in Tissue by Immune stain |
| 10487-7 | HMB-45 Ag [Presence] in Tissue by Immune stain |
| 10488-5 | IgA Ag [Presence] in Tissue by Immune stain |
| 10489-3 | IgA.heavy chain Ag [Presence] in Tissue by Immune stain |
| 10490-1 | IgE Ag [Presence] in Tissue by Immune stain |
| 10491-9 | IgG Ag [Presence] in Tissue by Immune stain |
| 10492-7 | IgG.heavy chain Ag [Presence] in Tissue by Immune stain |
| 10493-5 | IgM Ag [Presence] in Tissue by Immune stain |
| 10494-3 | IgM.heavy chain Ag [Presence] in Tissue by Immune stain |
| 10495-0 | Insulin Ag [Presence] in Tissue by Immune stain |
| 10496-8 | Kappa light chains Ag [Presence] in Tissue by Immune stain |
| 10497-6 | Immunoglobulin light chains.kappa amyloid Ag [Presence] in Tissue by Immune stain |
| 10498-4 | Keratin Ag [Presence] in Tissue by Immune stain |
| 10499-2 | Lambda light chains Ag [Presence] in Tissue by Immune stain |
| 105-7 | Ceforanide [Susceptibility] by Disk diffusion (KB) |
| 10500-7 | Immunoglobulin light chains.lambda amyloid Ag [Presence] in Tissue by Immune stain |
| 10501-5 | Lutropin [Units/volume] in Serum or Plasma |
| 10502-3 | Lutropin Ag [Presence] in Tissue by Immune stain |
| 10503-1 | Lysozyme Ag [Presence] in Tissue by Immune stain |
| 10504-9 | Myelin basic protein Ag [Presence] in Tissue by Immune stain |
| 10505-6 | Myoglobin Ag [Presence] in Tissue by Immune stain |
| 10506-4 | Peanut agglutinin Ag [Presence] in Tissue by Immune stain |
| 10507-2 | Prolactin Ag [Presence] in Tissue by Immune stain |
| 10508-0 | Prostate specific Ag [Presence] in Tissue by Immune stain |
| 10509-8 | Prostatic acid phosphatase Ag [Presence] in Tissue by Immune stain |
| 1051-2 | Hemolytic disease of newborn screen [Interpretation] in Blood |
| 10510-6 | S-100 Ag Ag [Presence] in Tissue by Immune stain |
| 10511-4 | Serotonin Ag [Presence] in Tissue by Immune stain |
| 10512-2 | Somatostatin Ag [Presence] in Tissue by Immune stain |
| 10513-0 | Somatotropin Ag [Presence] in Tissue by Immune stain |
| 10514-8 | Synaptophysin Ag [Presence] in Tissue by Immune stain |
| 10515-5 | Thyroglobulin Ag [Presence] in Tissue by Immune stain |
| 10516-3 | Thyrotropin Ag [Presence] in Tissue by Immune stain |
| 10517-1 | Trypsin Ag [Presence] in Tissue by Immune stain |
| 10518-9 | Ulex europaeus I lectin Ag [Presence] in Tissue by Immune stain |
| 10519-7 | Vimentin Ag [Presence] in Tissue by Immune stain |
| 10520-5 | Coagulation factor VI Ag [Presence] in Tissue by Immune stain |
| 10521-3 | Coagulation factor VIII Ag [Presence] in Tissue by Immune stain |
| 10522-1 | Coagulation factor XIII Ag [Presence] in Tissue by Immune stain |
| 10523-9 | Fibrinogen Ag [Presence] in Tissue by Immune stain |
| 10524-7 | Microscopic observation [Identifier] in Cervix by Cyto stain |
| 10525-4 | Microscopic observation [Identifier] in Unspecified specimen by Cyto stain |
| 10526-2 | Microscopic observation [Identifier] in Sputum by Cyto stain |
| 10527-0 | Microscopic observation [Identifier] in Tissue by Cyto stain |
| 10528-8 | Acetophenazine [Mass/volume] in Serum or Plasma |
| 10529-6 | Amoxapine metabolite [Mass/volume] in Serum or Plasma |
| 10530-4 | Aprobarbital [Mass/volume] in Serum or Plasma |
| 10531-2 | Bretylium [Mass/volume] in Serum or Plasma |
| 10533-8 | Propoxyphene+Acetaminophen [Mass/volume] in Serum or Plasma |
| 10534-6 | Diazoxide [Mass/volume] in Serum or Plasma |
| 10535-3 | Digoxin [Mass/volume] in Serum or Plasma |
| 10536-1 | Dipyridamole [Mass/volume] in Serum or Plasma |
| 10539-5 | Glipizide [Mass/volume] in Serum or Plasma |
| 10540-3 | Glyburide [Mass/volume] in Serum or Plasma |
| 10541-1 | Mepivacaine [Mass/volume] in Serum or Plasma |
| 10542-9 | Metharbital [Mass/volume] in Serum or Plasma |
| 10543-7 | Methsuximide+Normethsuximide [Mass/volume] in Serum or Plasma |
| 10544-5 | Normeperidine [Presence] in Serum or Plasma |
| 10545-2 | Normephenytoin [Mass/volume] in Serum or Plasma |
| 10546-0 | Normethsuximide [Mass/volume] in Serum or Plasma |
| 10547-8 | Primidone+PHENobarbital [Mass/volume] in Serum or Plasma |
| 10548-6 | Phenytoin Free/Phenytoin.total in Serum or Plasma |
| 10549-4 | Pirmenol [Mass/volume] in Serum or Plasma |
| 10551-0 | Triamterene [Mass/volume] in Serum or Plasma |
| 10552-8 | Tricyclic antidepressants [Mass/volume] in Serum or Plasma |
| 10553-6 | Prostatic acid phosphatase [Enzymatic activity/volume] in Genital fluid |
| 10555-1 | Acrosin [Entitic Catalytic Activity] in Spermatozoa |
| 10557-7 | Adenosine triphosphate [Moles/volume] in Semen |
| 10558-5 | Albumin [Moles/volume] in Semen |
| 10560-1 | Carcinoembryonic Ag [Units/volume] in Semen |
| 10561-9 | Carnitine [Moles/volume] in Semen |
| 10562-7 | Cells [#/volume] in Cervical mucus |
| 10563-5 | Cells other than spermatozoa [#/volume] in Semen |
| 10564-3 | Cervical mucus [Volume] |
| 10565-0 | Choriogonadotropin [Units/volume] in Semen |
| 10567-6 | Citrate [Moles/volume] in Semen |
| 10568-4 | Clarity of Semen |
| 10569-2 | Color of Semen |
| 10570-0 | Consistency of Cervical mucus |
| 10573-4 | Ferning [Type] in Cervical mucus |
| 10574-2 | Fructose [Moles/volume] in Semen |
| 10576-7 | Germ cells.immature [#/volume] in Semen |
| 10577-5 | Glucosidase [Enzymatic activity/volume] in Seminal plasma |
| 10578-3 | Glycerophosphocholine [Moles/volume] in Seminal plasma |
| 10579-1 | Leukocytes [#/volume] in Semen |
| 1058-7 | I Ab [Presence] in Serum or Plasma from Blood product unit |
| 10580-9 | Liquefaction [Time] in Semen |
| 10582-5 | pH of Cervical mucus |
| 10583-3 | Prostaglandin F1 alpha [Moles/volume] in Semen |
| 10585-8 | Round cells [#/volume] in Semen |
| 10587-4 | Sexual abstinence duration |
| 10588-2 | Spermatogonia [#/volume] in Semen |
| 10589-0 | Spermatids [#/volume] in Semen by Streptoavidin-biotin method (SAB) |
| 1059-5 | I Ab [Presence] in Serum or Plasma from Donor |
| 10590-8 | Spermatids [#/volume] in Semen by Sertoli cell barrier method (SCB) |
| 10591-6 | Primary Spermatocytes [#/volume] in Semen |
| 10592-4 | Secondary Spermatocytes [#/volume] in Semen |
| 10593-2 | Spermatozoa Pyriform Head/100 spermatozoa in Semen |
| 10594-0 | Spermatozoa Tapering Head/100 spermatozoa in Semen |
| 10599-9 | Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa by Kremer test |
| 106-5 | Ceforanide [Susceptibility] by Serum bactericidal titer |
| 1060-3 | I Ab [Presence] in Serum or Plasma |
| 10600-5 | Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa |
| 10601-3 | Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa --post coitus |
| 10602-1 | Spermatozoa Abnormal Head/100 spermatozoa in Semen |
| 10603-9 | Spermatozoa Abnormal Midpiece/100 spermatozoa in Semen |
| 10604-7 | Spermatozoa Abnormal Tail/100 spermatozoa in Semen |
| 10605-4 | Spermatozoa Agglutinated/100 spermatozoa in Semen |
| 10606-2 | Spermatozoa Amorphous Head/100 spermatozoa in Semen |
| 10607-0 | Spermatozoa Coiled Tail/100 spermatozoa in Semen |
| 10608-8 | Spermatozoa Cytoplasmic Droplet/100 spermatozoa in Semen |
| 10609-6 | Spermatozoa Duplicate Head/100 spermatozoa in Semen |
| 10610-4 | Spermatozoa Duplicate Tail/100 spermatozoa in Semen |
| 10611-2 | Spermatozoa Immotile/100 spermatozoa in Semen |
| 10612-0 | Spermatozoa Large Oval Head/100 spermatozoa in Semen |
| 10613-8 | Spermatozoa Viable/100 spermatozoa in Semen |
| 10614-6 | Spermatozoa Motile w IgA/100 spermatozoa in Semen by Immunobead |
| 10615-3 | Spermatozoa Motile w IgA/100 spermatozoa in Semen by Mixed antiglobulin reaction |
| 10616-1 | Spermatozoa Motile w IgG/100 spermatozoa in Semen by Immunobead |
| 10617-9 | Spermatozoa Motile w IgG/100 spermatozoa in Semen by Mixed antiglobulin reaction |
| 10618-7 | Spermatozoa Motile w IgM/100 spermatozoa in Semen by Immunobead |
| 10619-5 | Spermatozoa Motile w IgM/100 spermatozoa in Semen by Mixed antiglobulin reaction |
| 10620-3 | Spermatozoa Nonprogressive/100 spermatozoa in Semen |
| 10621-1 | Spermatozoa Normal Head/100 spermatozoa in Semen |
| 10622-9 | Spermatozoa Normal/100 spermatozoa in Semen |
| 10623-7 | Spermatozoa Pin Head/100 spermatozoa in Semen |
| 10624-5 | Spermatozoa Rapid/100 spermatozoa in Semen |
| 10625-2 | Spermatozoa Round Head/100 spermatozoa in Semen |
| 10626-0 | Spermatozoa Slow/100 spermatozoa in Semen |
| 10627-8 | Spermatozoa Small Oval Head/100 spermatozoa in Semen |
| 10628-6 | Spermatozoa Tail Swelling/100 spermatozoa in Semen |
| 10629-4 | Spermatozoa Vacuolated Head/100 spermatozoa in Semen |
| 10630-2 | Spinnbarkeit [Length] in Cervical mucus |
| 10631-0 | Testosterone [Moles/volume] in Semen |
| 10632-8 | Time until next menstrual period |
| 10633-6 | Zinc [Moles/volume] in Semen |
| 10634-4 | Complement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total in Serum or Plasma |
| 10635-1 | Acanthamoeba sp identified in Eye by Organism specific culture |
| 10636-9 | Acanthamoeba sp identified in Eye by Wet preparation |
| 10637-7 | Microscopic observation [Identifier] in Tissue by Night blue stain |
| 10638-5 | Thermophilic Actinomycetes colony count [#/volume] in Unspecified specimen by Organism specific culture |
| 10639-3 | Thermophilic Actinomycetes identified in Unspecified specimen by Organism specific culture |
| 10641-9 | Amoeba identified in Aspirate by Immune stain |
| 10642-7 | Amoeba identified in Aspirate by Wet preparation |
| 10643-5 | Amoeba identified in Stool by Organism specific culture |
| 10644-3 | Arthropod identified in Unspecified specimen |
| 10645-0 | Aspergillus fumigatus Ag [Presence] in Tissue by Immunofluorescence |
| 10646-8 | Astrovirus [Identifier] in Stool by Electron microscopy |
| 10647-6 | Babesia sp identified in Blood by Thick film |
| 10648-4 | Babesia sp identified in Blood by Thin film |
| 10649-2 | Calicivirus [Identifier] in Stool by Electron microscopy |
| 10650-0 | Candida sp DNA [Presence] in Blood by Probe with amplification |
| 10651-8 | Chlamydophila pneumoniae Ag [Presence] in Sputum or Bronchial |
| 10652-6 | Chlamydophila pneumoniae DNA [Presence] in Sputum or Bronchial by Probe with amplification |
| 10653-4 | Clotrimazole [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 10654-2 | Clotrimazole [Susceptibility] by Minimum lethal concentration (MLC) |
| 10655-9 | Coccidia identified in Duodenal fluid by Acid fast stain |
| 10656-7 | Coccidia identified in Stool by Acid fast stain |
| 10658-3 | Cyanobacterium identified in Water by Light microscopy |
| 10659-1 | Cyclospora sp identified in Stool by Acid fast stain |
| 10660-9 | Cytomegalovirus Ag [Presence] in Tissue by Immune stain |
| 10661-7 | Dinoflagellate identified in Water by Light microscopy |
| 10662-5 | Filaria identified in Blood by Concentration |
| 10663-3 | Filaria identified in Blood by Thick film |
| 10664-1 | Filaria identified in Blood by Thin film |
| 10665-8 | Fungus colony count [#/volume] in Unspecified specimen by Environmental culture |
| 10666-6 | Fungus identified in Tissue by Fontana-Masson stain |
| 10667-4 | Fungus identified in Unspecified specimen by Animal inoculation |
| 10668-2 | Fungus identified in Unspecified specimen by Environmental culture |
| 10669-0 | Fungus identified in Unspecified specimen by Sticky tape for environmental fungus |
| 1067-8 | Jk sup(a) Ab [Presence] in Serum or Plasma from Blood product unit |
| 10670-8 | Giardia lamblia [Presence] in Stool by Organism specific culture |
| 10671-6 | Helminth identified in Unspecified specimen |
| 10672-4 | Helminth+Arthropod identified in Unspecified specimen |
| 10673-2 | Hepatitis B virus core Ag [Presence] in Tissue by Immune stain |
| 10674-0 | Hepatitis B virus surface Ag [Presence] in Tissue by Immune stain |
| 10675-7 | Hepatitis B virus surface Ag [Presence] in Tissue by Orcein stain |
| 10676-5 | Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification |
| 10677-3 | Herpes simplex virus 1 Ag [Presence] in Tissue by Immune stain |
| 10678-1 | Herpes simplex virus 1+2 Ag [Presence] in Tissue by Immune stain |
| 10679-9 | Herpes simplex virus 2 Ag [Presence] in Tissue by Immune stain |
| 1068-6 | Jk sup(a) Ab [Presence] in Serum or Plasma from Donor |
| 10680-7 | Herpes simplex virus identified in Cerebral spinal fluid by Electron microscopy |
| 10681-5 | Herpes simplex virus identified in Tissue by Electron microscopy |
| 10683-1 | Hydatid cyst identified in Aspirate by Immune stain |
| 10684-9 | Hydatid cyst identified in Liver by Wet preparation |
| 10685-6 | Hydatid cyst identified in Lung tissue by Wet preparation |
| 10686-4 | Leishmania sp identified in Tissue by Giemsa stain |
| 10687-2 | Leishmania sp identified in Tissue by Organism specific culture |
| 10688-0 | Microscopic observation [Identifier] in Hair by KOH preparation |
| 10689-8 | Microscopic observation [Identifier] in Nail by KOH preparation |
| 1069-4 | Jk sup(a) Ab [Presence] in Serum or Plasma |
| 10690-6 | Microsporidia identified in Duodenal fluid by Trichrome stain modified |
| 10691-4 | Mushroom.toxic identified by Inspection |
| 10692-2 | Mushroom.toxic identified in Food by Light microscopy |
| 10693-0 | Mushroom.toxic identified in Vomitus by Light microscopy |
| 10694-8 | Naegleria sp identified in Tissue by Organism specific culture |
| 10695-5 | Naegleria sp identified in Tissue by Wet preparation |
| 10696-3 | Norovirus [Identifier] in Stool by Electron microscopy |
| 10697-1 | Nystatin [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 10698-9 | Nystatin [Susceptibility] by Minimum lethal concentration (MLC) |
| 10699-7 | Onchocerca sp identified in Tissue by Wet preparation |
| 107-3 | Cefotaxime [Susceptibility] by Minimum lethal concentration (MLC) |
| 1070-2 | Jk sup(a) Ag [Presence] on Red Blood Cells from Blood product unit |
| 10700-3 | Orthopoxvirus [Identifier] in Skin by Electron microscopy |
| 10701-1 | Ova and parasites identified in Stool by Concentration |
| 10702-9 | Ova and parasites identified in Stool by Immune stain |
| 10703-7 | Ova and parasites identified in Stool by Kinyoun iron hematoxylin stain |
| 10704-5 | Ova and parasites identified in Stool by Light microscopy |
| 10705-2 | Human papilloma virus Ag [Presence] in Tissue by Immune stain |
| 10706-0 | Picornavirus [Identifier] in Stool by Electron microscopy |
| 10707-8 | Toxic Plant identified in Plant specimen by Inspection |
| 10708-6 | Toxic Plant identified in Vomitus by Light microscopy |
| 10709-4 | Plasmodium falciparum Ag [Units/volume] in Blood by Immunofluorescence |
| 1071-0 | Jk sup(a) Ag [Presence] on Red Blood Cells from Donor |
| 10710-2 | Plasmodium sp identified in Blood by Thin film |
| 10711-0 | Plasmodium vivax Ag [Units/volume] in Blood by Immunofluorescence |
| 10712-8 | Pneumocystis sp identified in Lung tissue |
| 10713-6 | Prototheca identified in Unspecified specimen by Culture |
| 10715-1 | Schistosoma sp identified in Urine sediment by Light microscopy |
| 10716-9 | Schistosoma sp identified in Unspecified specimen by Organism specific culture |
| 10717-7 | Streptococcus pneumoniae Ab [Units/volume] in Serum by Latex agglutination |
| 10718-5 | Strongyloides sp Ab [Units/volume] in Serum by Immunoassay |
| 10719-3 | Taenia solium adult Ab [Units/volume] in Serum by Immunoblot |
| 1072-8 | Jk sup(a) Ag [Presence] on Red Blood Cells |
| 10720-1 | Terbinafine [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 10721-9 | Terbinafine [Susceptibility] by Minimum lethal concentration (MLC) |
| 10722-7 | Torovirus [Identifier] in Stool by Electron microscopy |
| 10723-5 | Toxoplasma gondii IgA Ab [Units/volume] in Serum by Immunoassay |
| 10724-3 | Toxoplasma gondii IgE Ab [Units/volume] in Serum by Immunoassay |
| 10725-0 | Toxoplasma gondii DNA [Units/volume] in Body fluid by Probe with amplification |
| 10726-8 | Toxoplasma gondii [Presence] in Tissue by Giemsa stain |
| 10727-6 | Toxoplasma gondii identified in Tissue |
| 10728-4 | Trichomonas sp identified in Genital specimen by Organism specific culture |
| 10729-2 | Trypanosoma sp identified in Blood by Light microscopy |
| 1073-6 | Jk sup(b) Ab [Presence] in Serum or Plasma from Blood product unit |
| 10730-0 | Trypanosoma sp identified in Blood by Organism specific culture |
| 10731-8 | Trypanosoma sp identified in Blood by Thick film |
| 10732-6 | Trypanosoma sp identified in Blood by Thin film |
| 10733-4 | Trypanosoma sp identified in Blood by Wet preparation |
| 10734-2 | Varicella zoster virus identified in Skin by Electron microscopy |
| 10736-7 | Virus identified in Cerebral spinal fluid by Electron microscopy |
| 10737-5 | Virus identified in Stool by Electron microscopy |
| 10738-3 | Virus identified in Tissue by Electron microscopy |
| 10739-1 | Virus identified in Unspecified specimen by Electron microscopy |
| 1074-4 | Jk sup(b) Ab [Presence] in Serum or Plasma from Donor |
| 10740-9 | Aluminum.microscopic observation [Identifier] in Bone by Histomorphometry stain |
| 10741-7 | Amyloid.microscopic observation [Identifier] in Brain by Thioflavine-S stain |
| 10742-5 | Amyloid.microscopic observation [Identifier] in Tissue by Bennhold stain.Putchler modified |
| 10743-3 | Amyloid.microscopic observation [Identifier] in Tissue by Highman stain |
| 10744-1 | Amyloid.microscopic observation [Identifier] in Tissue by Vassar-culling stain |
| 10745-8 | Bile.microscopic observation [Identifier] in Tissue by Fouchet stain |
| 10746-6 | Calcium.microscopic observation [Identifier] in Tissue by Von Kossa stain |
| 10747-4 | Collagen fibers+Elastic fibers.microscopic observation [Identifier] in Tissue by Lawson-Van Gieson stain |
| 10748-2 | Collagen fibers+Elastic fibers.microscopic observation [Identifier] in Tissue by Verhoeff-Van Gieson stain |
| 10749-0 | Collagen fibers.microscopic observation [Identifier] in Tissue by Van Gieson stain |
| 1075-1 | Jk sup(b) Ab [Presence] in Serum or Plasma |
| 10750-8 | Connective tissue.microscopic observation [Identifier] in Tissue by Trichrome stain.Masson |
| 10751-6 | Copper.microscopic observation [Identifier] in Tissue by Rhodamine stain |
| 10752-4 | Fat.microscopic observation [Identifier] in Milk by Sudan IV stain |
| 10753-2 | Fat.microscopic observation [Identifier] in Stool by Sudan IV stain |
| 10754-0 | Fat.microscopic observation [Identifier] in Tissue by Sudan IV stain |
| 10755-7 | Fungus.microscopic observation [Identifier] in Tissue by Methenamine silver stain.Grocott |
| 10756-5 | Glial fibers.microscopic observation [Identifier] in Tissue by Holzer stain |
| 10757-3 | Hematologic+Nuclear elements.microscopic observation [Identifier] in Tissue by Giemsa stain.May-Grunwald |
| 10758-1 | Iron.microscopic observation [Identifier] in Bone by Histomorphometry stain |
| 10759-9 | Iron.microscopic observation [Identifier] in Sputum by Gomori stain |
| 1076-9 | Jk sup(b) Ag [Presence] on Red Blood Cells from Blood product unit |
| 10760-7 | Iron.microscopic observation [Identifier] in Tissue by Gomori stain |
| 10761-5 | Iron.microscopic observation [Identifier] in Tissue by Other stain |
| 10762-3 | Microscopic observation [Identifier] in Blood by Hemosiderin stain |
| 10763-1 | Microscopic observation [Identifier] in Body fluid by Sudan black stain |
| 10764-9 | Microscopic observation [Identifier] in Sputum by Silver stain |
| 10765-6 | Microscopic observation [Identifier] in Tissue by Acetate esterase stain |
| 10766-4 | Microscopic observation [Identifier] in Tissue by Alcian blue stain |
| 10767-2 | Microscopic observation [Identifier] in Tissue by Alcian blue stain.sulfated |
| 10768-0 | Microscopic observation [Identifier] in Tissue by Alcian blue stain.with periodic acid-Schiff |
| 10769-8 | Microscopic observation [Identifier] in Tissue by Alizarin red S stain |
| 1077-7 | Jk sup(b) Ag [Presence] on Red Blood Cells from Donor |
| 10770-6 | Microscopic observation [Identifier] in Tissue by Argentaffin stain |
| 10772-2 | Microscopic observation [Identifier] in Tissue by Azure-eosin stain |
| 10773-0 | Microscopic observation [Identifier] in Tissue by Basic fuchsin stain |
| 10774-8 | Microscopic observation [Identifier] in Tissue by Bielschowsky stain |
| 10775-5 | Microscopic observation [Identifier] in Tissue by Bleach stain |
| 10776-3 | Microscopic observation [Identifier] in Tissue by Bodian stain |
| 10777-1 | Microscopic observation [Identifier] in Tissue by Brown and Brenn stain |
| 10778-9 | Microscopic observation [Identifier] in Tissue by Butyrate esterase stain |
| 10779-7 | Microscopic observation [Identifier] in Tissue by Carmine stain.Best |
| 1078-5 | Jk sup(b) Ag [Presence] on Red Blood Cells |
| 10780-5 | Microscopic observation [Identifier] in Tissue by Chloracetate esterase stain |
| 10781-3 | Microscopic observation [Identifier] in Tissue by Churukian-Schenk stain |
| 10782-1 | Microscopic observation [Identifier] in Tissue by Congo red stain |
| 10783-9 | Microscopic observation [Identifier] in Tissue by Crystal violet stain |
| 10784-7 | Microscopic observation [Identifier] in Tissue by Esterase stain.non-specific |
| 10785-4 | Microscopic observation [Identifier] in Tissue by Fite-Faraco stain |
| 10787-0 | Microscopic observation [Identifier] in Tissue by Gridley stain |
| 10788-8 | Microscopic observation [Identifier] in Tissue by Hansel stain |
| 10789-6 | Microscopic observation [Identifier] in Tissue by Hematoxylin-eosin-Harris regressive stain |
| 1079-3 | Js sup(a) Ab [Presence] in Serum or Plasma from Blood product unit |
| 10790-4 | Microscopic observation [Identifier] in Tissue by Hematoxylin-eosin-Mayers progressive stain |
| 10791-2 | Microscopic observation [Identifier] in Tissue by Mallory-Heidenhain stain |
| 10792-0 | Microscopic observation [Identifier] in Tissue by Methenamine silver stain.Jones |
| 10793-8 | Microscopic observation [Identifier] in Tissue by Methyl green stain |
| 10794-6 | Microscopic observation [Identifier] in Tissue by Methyl green-pyronine Y stain |
| 10795-3 | Microscopic observation [Identifier] in Tissue by Methyl violet stain |
| 10796-1 | Microscopic observation [Identifier] in Tissue by Mucicarmine stain |
| 10797-9 | Microscopic observation [Identifier] in Tissue by Neutral red stain |
| 10798-7 | Microscopic observation [Identifier] in Tissue by Oil red O stain |
| 10799-5 | Microscopic observation [Identifier] in Tissue by Pentachrome stain.Movat |
| 108-1 | Cefotaxime [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 1080-1 | Js sup(a) Ab [Presence] in Serum or Plasma from Donor |
| 10800-1 | Microscopic observation [Identifier] in Tissue by Periodic acid-Schiff stain with diatase digestion |
| 10801-9 | Microscopic observation [Identifier] in Tissue by Phosphotungstic acid Hematoxylin (PTAH) Stain |
| 10802-7 | Microscopic observation [Identifier] in Tissue by Prussian blue stain |
| 10803-5 | Microscopic observation [Identifier] in Tissue by Quinacrine fluorescent stain |
| 10804-3 | Microscopic observation [Identifier] in Tissue by Reticulin stain |
| 10805-0 | Microscopic observation [Identifier] in Tissue by Safranin stain |
| 10806-8 | Microscopic observation [Identifier] in Tissue by Schmorl stain |
| 10807-6 | Microscopic observation [Identifier] in Tissue by Sevier-Munger stain |
| 10808-4 | Microscopic observation [Identifier] in Tissue by Silver impregnation stain.Dieterle |
| 10809-2 | Microscopic observation [Identifier] in Tissue by Silver nitrate stain |
| 1081-9 | Js sup(a) Ab [Presence] in Serum or Plasma |
| 10810-0 | Microscopic observation [Identifier] in Tissue by Silver stain.Fontana-Masson |
| 10811-8 | Microscopic observation [Identifier] in Tissue by Silver stain.Grimelius |
| 10812-6 | Microscopic observation [Identifier] in Tissue by Steiner stain |
| 10813-4 | Microscopic observation [Identifier] in Tissue by Sudan black stain |
| 10814-2 | Microscopic observation [Identifier] in Tissue by Supravital stain |
| 10815-9 | Microscopic observation [Identifier] in Tissue by Tetrachrome stain |
| 10817-5 | Microscopic observation [Identifier] in Tissue by Trichrome stain.Gomori-Wheatley |
| 10818-3 | Microscopic observation [Identifier] in Tissue by Trichrome stain.Masson modified |
| 10819-1 | Microscopic observation [Identifier] in Tissue by Wade stain |
| 1082-7 | Js sup(a) Ag [Presence] on Red Blood Cells from Blood product unit |
| 10822-5 | Mucin.microscopic observation [Identifier] in Tissue by Mucicarmine stain.Mayer |
| 10823-3 | Mucopolysaccharides.microscopic observation [Identifier] in Tissue by Colloidal ferric oxide stain.Hale |
| 10824-1 | Myelin+Myelin breakdown products.microscopic observation [Identifier] in Tissue by Luxol fast blue/Periodic acid-Schiff stain |
| 10825-8 | Myelin+Nerve cells.microscopic observation [Identifier] in Tissue by Luxol fast blue/Cresyl violet stain |
| 10826-6 | Nissel.microscopic observation [Identifier] in Tissue by Cresyl echt violet stain |
| 10827-4 | Reticulum.microscopic observation [Identifier] in Tissue by Gomori stain |
| 10828-2 | Urate crystals.microscopic observation [type] in Tissue by De Galantha stain |
| 10829-0 | Silicon [Mass/volume] in Serum or Plasma |
| 1083-5 | Js sup(a) Ag [Presence] on Red Blood Cells from Donor |
| 10832-4 | Glucose [Mass/volume] in Serum or Plasma --15 minutes post 50 g lactose PO |
| 10833-2 | Insulin [Mass/volume] in Serum or Plasma --7 hours post 75 g glucose PO |
| 10834-0 | Globulin [Mass/volume] in Serum by calculation |
| 10835-7 | Lipoprotein a [Mass/volume] in Serum or Plasma |
| 10836-5 | Niacin [Mass/volume] in Blood |
| 10837-3 | Organic acids [Presence] in Serum or Plasma |
| 10838-1 | Phosphoserine [Mass/volume] in Serum or Plasma |
| 10839-9 | Troponin I.cardiac [Mass/volume] in Serum or Plasma |
| 1084-3 | Js sup(a) Ag [Presence] on Red Blood Cells |
| 10840-7 | Atropine [Mass/volume] in Urine |
| 10841-5 | methazolAMIDE [Mass/volume] in Serum or Plasma |
| 10846-4 | Borrelia burgdorferi DNA [Presence] in Blood by Probe with amplification |
| 10847-2 | Borrelia burgdorferi DNA [Presence] in Body fluid by Probe with amplification |
| 10848-0 | Chlamydia sp IgG Ab [Titer] in Serum by Immunofluorescence |
| 10849-8 | Chlamydia sp IgM Ab [Titer] in Serum by Immunofluorescence |
| 1085-0 | Js sup(b) Ab [Presence] in Serum or Plasma from Blood product unit |
| 10850-6 | Cyclospora cayetanensis [Presence] in Unspecified specimen |
| 10851-4 | Escherichia coli O157:H7 [Presence] in Stool by Organism specific culture |
| 10853-0 | Isospora belli [Presence] in Unspecified specimen by Acid fast stain.Kinyoun modified |
| 10855-5 | Ova and parasites identified in Duodenal fluid or Gastric fluid by Light microscopy |
| 10856-3 | Microscopic observation [Identifier] in Genital mucus by Gram stain |
| 10857-1 | Microsporidia identified in Unspecified specimen by Light microscopy |
| 10858-9 | Teichoate Ab [Presence] in Serum |
| 10859-7 | Trypanosoma sp [Identifier] in Blood by Acridine Orange + Giemsa Stain |
| 1086-8 | Js sup(b) Ab [Presence] in Serum or Plasma from Donor |
| 10860-5 | Varicella zoster virus [Presence] in Unspecified specimen by Organism specific culture |
| 10861-3 | Progesterone receptor [Mass/mass] in Tissue |
| 10862-1 | Basement membrane Ab [Titer] in Serum |
| 10863-9 | Endomysium IgA Ab [Titer] in Serum |
| 10864-7 | Immune complex [Units/volume] in Serum or Plasma by Raji cell assay |
| 10865-4 | Intercellular substance Ab [Presence] in Serum |
| 10866-2 | Sulfatide IgG Ab [Titer] in Serum |
| 10867-0 | Sulfatide IgM Ab [Titer] in Serum |
| 10868-8 | Bacitracin [Susceptibility] by Disk diffusion (KB) |
| 10869-6 | Xylose [Mass/volume] in Blood --3 hours post 25 g xylose PO |
| 1087-6 | Js sup(b) Ab [Presence] in Serum or Plasma |
| 10870-4 | Xylose [Mass/volume] in Blood --4 hours post 25 g xylose PO |
| 10871-2 | Xylose [Mass/volume] in Blood --5 hours post 25 g xylose PO |
| 10872-0 | Xylose [Mass/volume] in Blood --baseline |
| 10873-8 | Beta-2-Microglobulin [Mass/time] in 24 hour Urine |
| 10874-6 | Bombesin [Mass/volume] in Plasma |
| 10878-7 | Iodine.protein bound [Mass/volume] in Serum or Plasma |
| 1088-4 | Js sup(b) Ag [Presence] on Red Blood Cells from Blood product unit |
| 10880-3 | Magnesium [Mass/mass] in Stool |
| 10881-1 | Pentacarboxylporphyrins [Mass/volume] in Red Blood Cells |
| 10882-9 | Pentacarboxylporphyrins [Mass/volume] in Serum or Plasma |
| 10883-7 | Phenolphthalein [Mass/mass] in Stool |
| 10884-5 | Phosphate [Mass/mass] in Stool |
| 10885-2 | Porphyrins [Mass/time] in 24 hour Urine |
| 10886-0 | Prostate Specific Ag Free [Mass/volume] in Serum or Plasma |
| 10888-6 | Lipase [Enzymatic activity/volume] in Urine |
| 10889-4 | Bisacodyl [Mass/mass] in Stool |
| 1089-2 | Js sup(b) Ag [Presence] on Red Blood Cells from Donor |
| 10891-0 | Oxyphenisatin [Mass/mass] in Stool |
| 10892-8 | Pentoxifylline [Mass/volume] in Serum or Plasma |
| 10893-6 | Trenbolone [Mass/volume] in Urine |
| 10894-4 | Aspergillus niger Ab [Presence] in Serum by Immune diffusion (ID) |
| 10895-1 | Clostridioides difficile toxin B [Presence] in Stool |
| 10896-9 | Eastern equine encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence |
| 10897-7 | Eastern equine encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
| 10898-5 | Eastern equine encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence |
| 10899-3 | Eastern equine encephalitis virus IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
| 109-9 | Cefotaxime [Susceptibility] by Disk diffusion (KB) |
| 1090-0 | Js sup(b) Ag [Presence] on Red Blood Cells |
| 10900-9 | Hepatitis B virus surface Ab [Presence] in Serum by Immunoassay |
| 10901-7 | HIV 2 gp125 Ab [Presence] in Serum by Immunoblot |
| 10902-5 | HIV 2 gp36 Ab [Presence] in Serum by Immunoblot |
| 10903-3 | Hyaluronidase Ab [Titer] in Serum |
| 10904-1 | La Crosse virus IgG Ab [Titer] in Serum by Immunofluorescence |
| 10905-8 | La Crosse virus IgM Ab [Titer] in Serum by Immunofluorescence |
| 10906-6 | Saint Louis encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence |
| 10907-4 | Saint Louis encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence |
| 10909-0 | Benzidine [Mass/volume] in Urine |
| 1091-8 | K Ab [Presence] in Serum or Plasma from Blood product unit |
| 10910-8 | Borate [Mass/volume] in Urine |
| 10911-6 | Dichlorobenzidine [Mass/volume] in Urine |
| 10912-4 | Lead [Mass/volume] in Serum or Plasma |
| 10913-2 | 4,4'-Methylene bis(2-Chloroaniline) [Mass/volume] in Urine |
| 10914-0 | Methylenediamine [Mass/volume] in Urine |
| 10915-7 | Phencyclidine [Mass/volume] in Unspecified specimen |
| 10916-5 | Platinum [Mass/volume] in Blood |
| 10917-3 | Zinc [Mass/mass] in Stool |
| 10918-1 | Zinc [Mass/volume] in Unspecified specimen |
| 10919-9 | Anisakis IgE Ab [Units/volume] in Serum |
| 1092-6 | K Ab [Presence] in Serum or Plasma from Donor |
| 10920-7 | Bamboo shoot IgE Ab [Units/volume] in Serum |
| 10921-5 | Blomia tropicalis IgE Ab [Units/volume] in Serum |
| 10922-3 | Bovine serum albumin (BSA) IgE Ab [Units/volume] in Serum |
| 10923-1 | Bromelin IgE Ab [Units/volume] in Serum |
| 10924-9 | Starfruit IgE Ab [Units/volume] in Serum |
| 10925-6 | Chub Mackerel IgE Ab [Units/volume] in Serum |
| 10926-4 | Deer epithelium IgE Ab [Units/volume] in Serum |
| 10927-2 | Elk or Moose Meat IgE Ab [Units/volume] in Serum |
| 10928-0 | Fennel Fresh IgE Ab [Units/volume] in Serum |
| 10929-8 | Fennel Seed IgE Ab [Units/volume] in Serum |
| 1093-4 | K Ab [Presence] in Serum or Plasma |
| 10930-6 | Fish Feed IgE Ab [Units/volume] in Serum |
| 10931-4 | Daphnia (fish feed) IgE Ab [Units/volume] in Serum |
| 10932-2 | Tetramin IgE Ab [Units/volume] in Serum |
| 10933-0 | Guar gum IgE Ab [Units/volume] in Serum |
| 10934-8 | Guava IgE Ab [Units/volume] in Serum |
| 10935-5 | Horse serum proteins IgE Ab [Units/volume] in Serum |
| 10936-3 | Mare milk IgE Ab [Units/volume] in Serum |
| 10937-1 | Marjoram IgE Ab [Units/volume] in Serum |
| 10938-9 | Mediterranean flour moth IgE Ab [Units/volume] in Serum |
| 10939-7 | Whiff IgE Ab [Units/volume] in Serum |
| 1094-2 | K Ag [Presence] on Red Blood Cells from Blood product unit |
| 10940-5 | Cow milk boiled IgE Ab [Units/volume] in Serum |
| 10941-3 | Milk powder IgE Ab [Units/volume] in Serum |
| 10942-1 | Cockspur IgE Ab [Units/volume] in Serum |
| 10943-9 | Mink epithelium IgE Ab [Units/volume] in Serum |
| 10944-7 | Octopus IgE Ab [Units/volume] in Serum |
| 10945-4 | Papain IgE Ab [Units/volume] in Serum |
| 10946-2 | Passion fruit IgE Ab [Units/volume] in Serum |
| 10947-0 | Persimmon IgE Ab [Units/volume] in Serum |
| 10948-8 | Pigeon feather IgE Ab [Units/volume] in Serum |
| 10949-6 | Malassezia furfur IgE Ab [Units/volume] in Serum |
| 1095-9 | K Ag [Presence] on Red Blood Cells from Donor |
| 10950-4 | Reindeer epithelium IgE Ab [Units/volume] in Serum |
| 10951-2 | Sericin IgE Ab [Units/volume] in Serum |
| 10952-0 | Swine urine proteins IgE Ab [Units/volume] in Serum |
| 10953-8 | Timothy IgG Ab [Units/volume] in Serum |
| 10954-6 | Pine Nut IgE Ab [Units/volume] in Serum |
| 10955-3 | Long Leaf Pine IgE Ab [Units/volume] in Serum |
| 10956-1 | Short Leaf Pine IgE Ab [Units/volume] in Serum |
| 10957-9 | Slash Pine IgE Ab [Units/volume] in Serum |
| 10958-7 | Virginia Scrub Pine IgE Ab [Units/volume] in Serum |
| 10959-5 | Plaice IgE Ab [Units/volume] in Serum |
| 1096-7 | K Ag [Presence] on Red Blood Cells |
| 10960-3 | Rabbit serum proteins IgE Ab [Units/volume] in Serum |
| 10961-1 | Rabbit urine proteins IgE Ab [Units/volume] in Serum |
| 10963-7 | Spondylocladium citrovirens IgE Ab [Units/volume] in Serum |
| 10964-5 | 17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --15 minutes post 250 ug corticotropin IM |
| 10965-2 | 17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IM |
| 10966-0 | Glucose [Presence] in Urine by Test strip --2.5 hours post 75 g glucose PO |
| 10967-8 | Glucose [Presence] in Urine by Test strip --3.5 hours post 75 g glucose PO |
| 10968-6 | Glucose [Presence] in Urine by Test strip --4.5 hours post 75 g glucose PO |
| 10969-4 | Cystine+Homocysteine [Presence] in Urine |
| 1097-5 | Kp sup(a) Ab [Presence] in Serum or Plasma from Blood product unit |
| 10970-2 | Galactose 1 phosphate uridyl transferase [Enzymatic activity/volume] in Blood |
| 10971-0 | Lysozyme [Mass/volume] in Urine |
| 10973-6 | 3 methoxy O desmethylencainide [Mass/volume] in Serum or Plasma |
| 10974-4 | 5-Fluorocytosine [Mass/volume] in Urine |
| 10975-1 | 6-Monoacetylmorphine (6-MAM) [Mass/volume] in Urine |
| 10976-9 | 6-Monoacetylmorphine (6-MAM) [Presence] in Urine |
| 10977-7 | ALPRAZolam [Mass/volume] in Blood |
| 10978-5 | Amitriptyline+Nortriptyline [Mass/volume] in Urine |
| 10979-3 | Carisoprodol [Mass/volume] in Urine |
| 1098-3 | Kp sup(a) Ab [Presence] in Serum or Plasma from Donor |
| 10980-1 | Cephapirin [Mass/volume] in Serum or Plasma |
| 10981-9 | cloNIDine [Mass/volume] in Urine |
| 10982-7 | Demeclocycline [Mass/volume] in Serum or Plasma |
| 10983-5 | Norparamethadione [Mass/volume] in Serum or Plasma |
| 10984-3 | Dicloxacillin [Mass/volume] in Serum or Plasma |
| 10985-0 | Doxapram [Mass/volume] in Serum or Plasma |
| 10986-8 | Doxycycline [Mass/volume] in Serum or Plasma |
| 10987-6 | Fluconazole [Mass/volume] in Serum or Plasma |
| 10988-4 | fluvoxaMINE [Mass/volume] in Serum or Plasma |
| 10989-2 | Itraconazole [Mass/volume] in Serum or Plasma |
| 1099-1 | Kp sup(a) Ab [Presence] in Serum or Plasma |
| 10990-0 | Ketoconazole [Mass/volume] in Serum or Plasma |
| 10991-8 | metroNIDAZOLE [Mass/volume] in Serum or Plasma |
| 10992-6 | Norclozapine [Mass/volume] in Serum or Plasma |
| 10993-4 | Nafcillin [Mass/volume] in Serum or Plasma |
| 10994-2 | Naltrexone [Mass/volume] in Serum or Plasma |
| 10995-9 | Neomycin [Mass/volume] in Serum or Plasma |
| 10996-7 | Normeperidine [Mass/volume] in Serum or Plasma |
| 10997-5 | O-desmethylencainide [Mass/volume] in Serum or Plasma |
| 10998-3 | oxyCODONE [Presence] in Urine |
| 10999-1 | Paramethadione [Mass/volume] in Serum or Plasma |
| 11-7 | Amikacin [Susceptibility] by Minimum lethal concentration (MLC) |
| 110-7 | Cefotaxime [Susceptibility] by Serum bactericidal titer |
| 1100-7 | Kp sup(a) Ag [Presence] on Red Blood Cells from Blood product unit |
| 11000-7 | Promethazine [Presence] in Urine |
| 11001-5 | Pyrazinamide [Mass/volume] in Serum or Plasma |
| 11002-3 | Scopolamine [Presence] in Urine |
| 11003-1 | Ticlopidine [Mass/volume] in Serum or Plasma |
| 11004-9 | Tricyclic antidepressants [Presence] in Urine |
| 11005-6 | Trimethoprim [Mass/volume] in Serum or Plasma |
| 11006-4 | Borrelia burgdorferi Ab [Presence] in Serum |
| 11007-2 | Borrelia burgdorferi Ag [Units/volume] in Urine |
| 11008-0 | Cytomegalovirus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
| 11009-8 | Epstein Barr virus capsid IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
| 1101-5 | Kp sup(a) Ag [Presence] on Red Blood Cells from Donor |
| 11010-6 | Epstein Barr virus capsid IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence |
| 11011-4 | Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection |
| 11012-2 | Reovirus Ab [Titer] in Serum by Complement fixation |
| 11013-0 | DNA double strand Ab [Titer] in Serum |
| 11014-8 | Somatotropin Ab [Titer] in Serum or Plasma |
| 11015-5 | Somatotropin binding protein [Moles/volume] in Serum or Plasma |
| 11016-3 | Microscopic observation [Identifier] in Blood or Marrow by Esterase stain.non-specific |
| 11017-1 | Microscopic observation [Identifier] in Blood or Marrow by Chloracetate esterase stain |
| 11018-9 | Microscopic observation [Identifier] in Blood or Marrow by Peroxidase stain |
| 11019-7 | Microscopic observation [Identifier] in Blood or Marrow by Sudan black B stain |
| 1102-3 | Kp sup(a) Ag [Presence] on Red Blood Cells |
| 11020-5 | Microscopic observation [Identifier] in Blood or Marrow by Tartrate-resistant acid phosphatase stain |
| 11021-3 | Microscopic observation [Identifier] in Blood or Marrow by Terminal deoxynucleotidyl transferase stain |
| 11024-7 | Benzodiazepines [Mass/volume] in Serum or Plasma |
| 11027-0 | Propoxyphene [Mass/volume] in Meconium |
| 11028-8 | Zinc [Mass/volume] in Body fluid |
| 11029-6 | Consistency of Stool |
| 1103-1 | Kp sup(b) Ab [Presence] in Serum or Plasma from Blood product unit |
| 11030-4 | Aspergillus fumigatus+Aspergillus niger IgE Ab [Units/volume] in Serum |
| 11031-2 | Lymphocytes/100 leukocytes in Body fluid |
| 11032-0 | Glucose [Mass/volume] in Serum or Plasma --45 minutes post 50 g lactose PO |
| 11034-6 | Acetylcholine receptor binding Ab [Moles/volume] in Serum |
| 11035-3 | Adenylate kinase [Enzymatic activity/volume] in Red Blood Cells |
| 11037-9 | Alpha-N-acetylgalactosaminidase [Enzymatic activity/volume] in Serum or Plasma |
| 11038-7 | Beta+gamma tocopherol [Mass/volume] in Serum or Plasma |
| 11039-5 | C reactive protein [Presence] in Serum or Plasma |
| 1104-9 | Kp sup(b) Ab [Presence] in Serum or Plasma from Donor |
| 11040-3 | Cortisol Free [Mass/volume] in Urine |
| 11041-1 | Creatinine [Mass/volume] in Serum or Plasma --post dialysis |
| 11042-9 | Creatinine [Mass/volume] in Serum or Plasma --pre dialysis |
| 11043-7 | Cryofibrinogen [Presence] in Plasma |
| 11044-5 | Diphosphoglycerate mutase [Enzymatic activity/volume] in Red Blood Cells |
| 11045-2 | Enolase [Enzymatic activity/volume] in Red Blood Cells |
| 11046-0 | EPINEPHrine [Mass/volume] in Urine |
| 11047-8 | Glucose phosphate isomerase [Enzymatic activity/volume] in Red Blood Cells |
| 11048-6 | Glyceraldehyde 3 phosphate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells |
| 1105-6 | Kp sup(b) Ab [Presence] in Serum or Plasma |
| 11050-2 | Kappa light chains [Mass/volume] in Serum or Plasma |
| 11051-0 | Lambda light chains [Mass/volume] in Serum or Plasma |
| 11052-8 | Ketamine [Mass/volume] in Urine |
| 11053-6 | Lactate dehydrogenase [Enzymatic activity/volume] in Red Blood Cells |
| 11054-4 | Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma |
| 11055-1 | Melatonin [Mass/volume] in Serum or Plasma |
| 11056-9 | Melatonin [Flow] in 24 hour Urine |
| 11057-7 | Monophosphoglyceromutase [Enzymatic activity/volume] in Red Blood Cells |
| 11058-5 | Phosphofructokinase [Enzymatic activity/volume] in Red Blood Cells |
| 11059-3 | Phosphoglycerate kinase [Enzymatic activity/volume] in Red Blood Cells |
| 1106-4 | Kp sup(b) Ag [Presence] on Red Blood Cells from Blood product unit |
| 11060-1 | Reducing substances [Presence] in Stool |
| 11061-9 | 11-Dehydro thromboxane beta 2 [Mass/time] in 24 hour Urine |
| 11062-7 | Thyroxine (T4).albumin bound [Mass/volume] in Serum or Plasma |
| 11063-5 | Triosephosphate isomerase [Enzymatic activity/volume] in Red Blood Cells |
| 11064-3 | Urea nitrogen [Mass/volume] in Serum or Plasma --post dialysis |
| 11065-0 | Urea nitrogen [Mass/volume] in Serum or Plasma --pre dialysis |
| 11066-8 | Uroporphyrinogen III synthase [Enzymatic activity/volume] in Red Blood Cells |
| 11067-6 | Bleeding time |
| 11068-4 | Microscopic observation [Identifier] in Body fluid by Cyto stain |
| 11069-2 | Microscopic observation [Identifier] in Gastric fluid by Cyto stain |
| 1107-2 | Kp sup(b) Ag [Presence] on Red Blood Cells from Donor |
| 11070-0 | Microscopic observation [Identifier] in Urine by Cyto stain |
| 11071-8 | Butalbital [Mass/volume] in Urine |
| 11072-6 | Despropionylfentanyl [Mass/volume] in Serum or Plasma |
| 11073-4 | Despropionylfentanyl [Mass/volume] in Urine |
| 11074-2 | Norfentanyl [Mass/volume] in Serum or Plasma |
| 11075-9 | Norfentanyl [Mass/volume] in Urine |
| 11076-7 | Hepatitis C virus 5-1-1 Ab [Presence] in Serum by Immunoblot |
| 11077-5 | Hepatitis C virus superoxide dismutase Ab [Presence] in Serum by Immunoblot |
| 11078-3 | HIV 2 gp80 Ab [Presence] in Serum by Immunoblot |
| 11079-1 | HIV 2 p26 Ab [Presence] in Serum by Immunoblot |
| 1108-0 | Kp sup(b) Ag [Presence] on Red Blood Cells |
| 11080-9 | HIV 2 p53 Ab [Presence] in Serum by Immunoblot |
| 11081-7 | HIV 2 p56 Ab [Presence] in Serum by Immunoblot |
| 11082-5 | HIV 2 p68 Ab [Presence] in Serum by Immunoblot |
| 11083-3 | Human papilloma virus identified in Cervix |
| 11084-1 | Reagin Ab [Titer] in Serum |
| 11085-8 | Schistosoma sp identified in Stool by Concentration |
| 11086-6 | Streptococcus pneumoniae Ag [Presence] in Serum |
| 11087-4 | Insulin Ab [Titer] in Serum |
| 11088-2 | Neuronal nuclear Ab [Presence] in Serum |
| 11089-0 | Neuronal nuclear Ab [Presence] in Cerebral spinal fluid |
| 11090-8 | Smith extractable nuclear Ab [Units/volume] in Serum |
| 11091-6 | Alpha chlordane [Mass/volume] in Serum or Plasma |
| 11092-4 | Barbiturates [Mass/mass] in Hair |
| 11093-2 | Dichlorodiphenyldichloroethylene [Mass/volume] in Serum or Plasma |
| 11094-0 | Dichlorodiphenyltrichloroethane [Mass/volume] in Serum or Plasma |
| 11095-7 | Dieldrin [Mass/volume] in Serum or Plasma |
| 11096-5 | Gamma chlordane [Mass/volume] in Serum or Plasma |
| 11097-3 | Lindane [Mass/volume] in Serum or Plasma |
| 11098-1 | Malaoxon [Mass/volume] in Serum or Plasma |
| 11099-9 | Methoxychlor [Mass/volume] in Serum or Plasma |
| 111-5 | cefoTEtan [Susceptibility] by Minimum lethal concentration (MLC) |
| 1110-6 | Le sup(a) Ab [Presence] in Serum or Plasma from Blood product unit |
| 11100-5 | Tetrachloroethylene [Mass/volume] in Blood |
| 11101-3 | Bacteria [#/area] in Synovial fluid by Microscopy high power field |
| 11102-1 | Charcot-leyden crystals [type] in Unspecified specimen by Trichrome stain |
| 11103-9 | Band form neutrophils/100 cells in Bone marrow by Manual count |
| 11104-7 | Normoblasts Basophilic/100 cells in Bone marrow by Manual count |
| 11105-4 | Basophils/100 cells in Bone marrow by Manual count |
| 11106-2 | Eosinophils/100 cells in Bone marrow by Manual count |
| 11107-0 | Variant lymphocytes/100 cells in Bone marrow by Manual count |
| 11108-8 | Lymphocytes/100 cells in Bone marrow by Manual count |
| 11109-6 | Mast cells/100 cells in Bone marrow by Manual count |
| 1111-4 | Le sup(a) Ab [Presence] in Serum or Plasma from Donor |
| 11110-4 | Megakaryocytes/100 cells in Bone marrow by Manual count |
| 11111-2 | Metamyelocytes/100 cells in Bone marrow by Manual count |
| 11112-0 | Monocytes/100 cells in Bone marrow by Manual count |
| 11113-8 | Myeloblasts/100 cells in Bone marrow by Manual count |
| 11114-6 | Myelocytes/100 cells in Bone marrow by Manual count |
| 11115-3 | Neutrophils/100 cells in Bone marrow by Manual count |
| 11116-1 | Normoblasts Orthochromic/100 cells in Bone marrow by Manual count |
| 11117-9 | Plasma cells immature/100 cells in Bone marrow by Manual count |
| 11118-7 | Plasma cells/100 cells in Bone marrow by Manual count |
| 11119-5 | Normoblasts Polychromatophilic/100 cells in Bone marrow by Manual count |
| 1112-2 | Le sup(a) Ab [Presence] in Serum or Plasma |
| 11120-3 | Promyelocytes/100 cells in Bone marrow by Manual count |
| 11121-1 | Prolymphocytes/100 cells in Bone marrow by Manual count |
| 11122-9 | Promonocytes/100 cells in Bone marrow by Manual count |
| 11124-5 | Pronormoblasts/100 cells in Bone marrow by Manual count |
| 11125-2 | Platelet morphology finding [Identifier] in Blood |
| 11126-0 | Platelets [Morphology] in Bone marrow |
| 11127-8 | Erythrocytes [Morphology] in Bone marrow |
| 11128-6 | Segmented neutrophils/100 cells in Bone marrow |
| 11129-4 | Pronormoblasts [#/volume] in Blood |
| 1113-0 | Le sup(a) Ag [Presence] on Red Blood Cells from Blood product unit |
| 11130-2 | B lymphocytes [#/volume] in Blood |
| 11133-6 | Catecholamines Free [Mass/volume] in Urine |
| 11134-4 | Appearance of Spun Body fluid |
| 11135-1 | Appearance of Spun Cerebral spinal fluid |
| 11138-5 | Myeloid cells/Erythroid cells [# Ratio] in Bone marrow |
| 11139-3 | Metanephrine [Mass/volume] in Urine |
| 1114-8 | Le sup(a) Ag [Presence] on Red Blood Cells from Donor |
| 11140-1 | Metanephrine [Moles/time] in 24 hour Urine |
| 11141-9 | Phosphate/Creatinine [Mass Ratio] in Urine |
| 11142-7 | Glucose [Mass/volume] in Serum or Plasma --15 minutes post 100 g glucose PO |
| 11143-5 | Glucose [Mass/volume] in Serum or Plasma --45 minutes post 100 g glucose PO |
| 11144-3 | Homovanillate [Mass/volume] in Urine |
| 11145-0 | 5-Hydroxyindoleacetate/Creatinine [Mass Ratio] in Urine |
| 11146-8 | Homovanillate/Creatinine [Mass Ratio] in Urine |
| 11147-6 | Myoglobin/Creatinine [Mass Ratio] in Urine |
| 1115-5 | Le sup(a) Ag [Presence] on Red Blood Cells |
| 11150-0 | Blasts/100 cells in Bone marrow |
| 11151-8 | Hematocrit [Volume Fraction] of Cord blood |
| 11152-6 | Eosinophils/100 cells in Bone marrow |
| 11153-4 | Hematocrit [Volume Fraction] of Body fluid |
| 11154-2 | Cholinesterase [Enzymatic activity/volume] in Blood |
| 11155-9 | Cortisol/Creatinine [Mass Ratio] in Urine |
| 11156-7 | Leukocyte morphology finding [Identifier] in Blood |
| 11157-5 | Leukocytes [Morphology] in Bone marrow |
| 11158-3 | Appearance of Serum |
| 11159-1 | Alkalase IgE Ab [Units/volume] in Serum |
| 1116-3 | Le sup(b) Ab [Presence] in Serum or Plasma from Blood product unit |
| 11160-9 | Beta lactoglobulin IgG Ab [Units/volume] in Serum |
| 11161-7 | Wheat Bran IgE Ab [Units/volume] in Serum |
| 11163-3 | Carageenan IgE Ab [Units/volume] in Serum |
| 11164-1 | Cream Cheese IgE Ab [Units/volume] in Serum |
| 11165-8 | Chinchilla IgE Ab [Units/volume] in Serum |
| 11166-6 | Chortoglyphus arcuatus IgE Ab [Units/volume] in Serum |
| 11167-4 | Cockatiel feather IgE Ab [Units/volume] in Serum |
| 11168-2 | Arizona Cypress IgE Ab [Units/volume] in Serum |
| 11169-0 | Deer hair IgE Ab [Units/volume] in Serum |
| 1117-1 | Le sup(b) Ab [Presence] in Serum or Plasma from Donor |
| 11170-8 | Dematiaceae IgE Ab [Units/volume] in Serum |
| 11171-6 | Erythromycin IgE Ab [Units/volume] in Serum |
| 11172-4 | Ferret epithelium IgE Ab [Units/volume] in Serum |
| 11173-2 | Fig IgE Ab [Units/volume] in Serum |
| 11174-0 | Grain weevel IgE Ab [Units/volume] in Serum |
| 11175-7 | Helminthosporium sativum IgE Ab [Units/volume] in Serum |
| 11176-5 | Lactalbumin alpha IgG Ab [Units/volume] in Serum |
| 11177-3 | Lactalbumin beta IgE Ab [Units/volume] in Serum |
| 11178-1 | Beta galactosidase IgE Ab [Units/volume] in Serum |
| 11179-9 | Linden IgE Ab [Units/volume] in Serum |
| 1118-9 | Le sup(b) Ab [Presence] in Serum or Plasma |
| 11180-7 | Lupin IgE Ab [Units/volume] in Serum |
| 11181-5 | Lycopodium spp IgE Ab [Units/volume] in Serum |
| 11182-3 | Lysozyme IgE Ab [Units/volume] in Serum |
| 11183-1 | Macadamia IgE Ab [Units/volume] in Serum |
| 11184-9 | Scad IgE Ab [Units/volume] in Serum |
| 11185-6 | Maxatase IgE Ab [Units/volume] in Serum |
| 11186-4 | Foxtail Millet IgE Ab [Units/volume] in Serum |
| 11187-2 | Penicillium frequentans IgE Ab [Units/volume] in Serum |
| 11188-0 | Cayenne IgE Ab [Units/volume] in Serum |
| 11189-8 | Jalepeno Pepper IgE Ab [Units/volume] in Serum |
| 1119-7 | Le sup(b) Ag [Presence] on Red Blood Cells from Blood product unit |
| 11190-6 | Mint IgE Ab [Units/volume] in Serum |
| 11191-4 | Pollock IgE Ab [Units/volume] in Serum |
| 11192-2 | Protamine IgE Ab [Units/volume] in Serum |
| 11193-0 | Pumpkin Seed IgE Ab [Units/volume] in Serum |
| 11194-8 | Rape Pollen IgE Ab [Units/volume] in Serum |
| 11195-5 | Rapeseed IgE Ab [Units/volume] in Serum |
| 11196-3 | Orange roughy IgE Ab [Units/volume] in Serum |
| 11197-1 | Sardine (pilchard) IgE Ab [Units/volume] in Serum |
| 11198-9 | Shark IgE Ab [Units/volume] in Serum |
| 11199-7 | Silver IgE Ab [Units/volume] in Serum |
| 112-3 | cefoTEtan [Susceptibility] by Minimum inhibitory concentration (MIC) |
| 1120-5 | Le sup(b) Ag [Presence] on Red Blood Cells from Donor |
| 11200-3 | Escargot IgE Ab [Units/volume] in Serum |
| 11201-1 | Succinylcholine IgE Ab [Units/volume] in Serum |
| 11202-9 | Tarragon IgE Ab [Units/volume] in Serum |
| 11203-7 | Trichosporon pullulans IgE Ab [Units/volume] in Serum |
| 11204-5 | Ulocladium chartarum IgE Ab [Units/volume] in Serum |
| 11206-0 | 18-Hydroxydeoxycorticosterone [Mass/volume] in Serum or Plasma |
| 11207-8 | Alpha-1-Fetoprotein [Mass/volume] in Body fluid |
| 11208-6 | Atrial natriuretic factor [Mass/volume] in Plasma |
| 11209-4 | Beta glucuronidase [Enzymatic activity/volume] in Cerebral spinal fluid |
| 1121-3 | Le sup(b) Ag [Presence] on Red Blood Cells |
| 11210-2 | Cancer Ag 125 [Units/volume] in Body fluid |
| 11211-0 | Carbon dioxide, total [Moles/volume] in Body fluid |
| 11212-8 | Coproporphyrin [Mass/volume] in Urine |
| 11213-6 | Corticotropin releasing hormone [Mass/volume] in Serum or Plasma |
| 11215-1 | Delta aminolevulinate [Mass/volume] in Urine |
| 11218-5 | Microalbumin [Mass/volume] in Urine by Test strip |
| 11219-3 | Immunoglobulin light chains [Presence] in Serum |
| 1122-1 | Le sup(x) Ab [Presence] in Serum or Plasma from Blood product unit |
| 11220-1 | Iodine Free [Mass/time] in 24 hour Urine |
| 11221-9 | Pentacarboxylporphyrins [Mass/volume] in Urine |
| 11222-7 | Pentacarboxylporphyrins [Presence] in Urine |
| 11224-3 | Phosphoethanolamine [Mass/volume] in Cerebral spinal fluid |
| 11225-0 | Porphyrins [Mass/volume] in Urine |
| 11226-8 | Prorenin [Units/volume] in Plasma |
| 11227-6 | Pyruvate kinase [Presence] in Blood |
| 11228-4 | Uroporphyrin [Mass/volume] in Urine |
| 11229-2 | 3-O-Methyldopa [Mass/volume] in Serum or Plasma |
| 1123-9 | Le sup(x) Ab [Presence] in Serum or Plasma from Donor |
| 11230-0 | Amobarbital [Mass/volume] in Urine |
| 11231-8 | Astemizole [Mass/volume] in Serum or Plasma |
| 11232-6 | Bromocriptine [Mass/volume] in Serum or Plasma |
| 11233-4 | Brompheniramine [Mass/volume] in Serum or Plasma |
| 11234-2 | Propoxyphene [Mass/mass] in Hair |
| 11235-9 | fentaNYL [Presence] in Urine |
| 11236-7 | Gemfibrozil [Mass/volume] in Serum or Plasma |
| 11237-5 | hydrALAZINE [Mass/volume] in Serum or Plasma |
| 11238-3 | Hydroxyalprazolam [Mass/volume] in Urine |
| 1124-7 | Le sup(x) Ab [Presence] in Serum or Plasma |
| 11240-9 | hydrOXYzine [Mass/volume] in Urine |
| 11241-7 | Hyoscyamine [Mass/volume] in Serum or Plasma |
| 11242-5 | Mercaptopurine [Mass/volume] in Serum or Plasma |
| 11243-3 | Methadone [Mass/mass] in Hair |
| 11244-1 | Morphine Free [Mass/volume] in Serum or Plasma |
| 11246-6 | oxyCODONE [Mass/volume] in Urine |
| 11247-4 | oxyMORphone [Presence] in Urine |
| 11248-2 | Pergolide [Mass/volume] in Serum or Plasma |
| 11249-0 | Phenacemide [Mass/volume] in Serum or Plasma |
| 1125-4 | Le Ab [Presence] in Serum or Plasma from Blood product unit |
| 11250-8 | Phenylethylmalonate [Mass/volume] in Serum or Plasma |
| 11251-6 | Piroxicam [Mass/volume] in Serum or Plasma |
| 11252-4 | Scopolamine [Mass/volume] in Serum or Plasma |
| 11253-2 | Tacrolimus [Mass/volume] in Blood |
| 11254-0 | Chlamydophila pneumoniae Ab [Titer] in Serum |
| 11255-7 | Haemophilus ducreyi [Presence] in Unspecified specimen by Organism specific culture |
| 11256-5 | Haemophilus influenzae B IgG Ab [Mass/volume] in Serum |
| 11257-3 | Haemophilus influenzae B IgG Ab [Mass/volume] in Serum by Immunoassay |
| 11258-1 | Hepatitis B virus DNA [Units/volume] in Serum |
| 10154-3 | Chief complaint Narrative - Reported |
| 10155-0 | History of allergies, reported |
| 10156-8 | History of Childhood diseases Narrative |
| 10158-4 | History of Functional status Narrative |
| 10159-2 | History of Industrial exposure Narrative |
| 10160-0 | History of Medication use Narrative |
| 10161-8 | History of Occupational exposure Narrative |
| 10164-2 | History of Present illness Narrative |
| 10166-7 | History of Social function Narrative |
| 10167-5 | History of Surgical procedures Narrative |
| 10182-4 | History of Travel Narrative |
| 10183-2 | Hospital discharge medications Narrative |
| 10184-0 | Hospital discharge physical findings Narrative |
| 10185-7 | Hospital discharge procedures Narrative |
| 10186-5 | Identifying information Narrative Observed |
| 10187-3 | Review of systems Narrative - Reported |
| 10188-1 | Review of systems overview Narrative - Reported |
| 10189-9 | Review of systems overview - Reported |
| 10190-7 | Mental status Narrative |
| 10213-7 | Surgical operation note anesthesia Narrative |
| 10215-2 | Surgical operation note findings Narrative |
| 10216-0 | Surgical operation note fluids Narrative |
| 10217-8 | Surgical operation note indications [Interpretation] Narrative |
| 10218-6 | Surgical operation note postoperative diagnosis Narrative |
| 10219-4 | Surgical operation note preoperative diagnosis Narrative |
| 10221-0 | Surgical operation note specimens taken Narrative |
| 10222-8 | Surgical operation note surgical complications [Interpretation] Narrative |
| 10223-6 | Surgical operation note surgical procedure Narrative |
| 10224-4 | Hemodynamic method special circumstances |
| 10322-6 | Potassium intake 24 hour |
| 10831-6 | Surgical operation note complications [Interpretation] |
| 11283-9 | Acuity assessment [Function] at First encounter |
| 11286-2 | Alcohol binge episodes per month - Reported |
| 11287-0 | Alcoholic drinks per drinking day - Reported |
| 11288-8 | Arrival time documented |
| 11289-6 | Body temperature at First encounter |
| 11294-6 | Current employment Narrative - Reported |
| 11295-3 | Current employment - Reported |
| 11300-1 | ED diagnosis |
| 11301-9 | ED diagnosis type |
| 11302-7 | ED discharge disposition |
| 11303-5 | ED disposition consult/referral |
| 11310-0 | ED patient satisfaction report type |
| 11313-4 | ED procedure result observation [Interpretation] |
| 11314-2 | ED procedure result type |
| 11315-9 | ED service level |
| 11320-9 | Feeding and dietary status Narrative - Reported |
| 11321-7 | Feeding and dietary status - Reported |
| 11322-5 | History of General health Narrative |
| 11323-3 | General health - Reported |
| 11324-1 | Glasgow coma score eye opening at First encounter |
| 11325-8 | Glasgow coma score motor at First encounter |
| 11326-6 | Glasgow coma score verbal at First encounter |
| 11329-0 | History general Narrative - Reported |
| 11330-8 | History of Alcohol use Narrative |
| 11331-6 | History of Alcohol use |
| 11332-4 | History of Cognitive function Narrative |
| 11333-2 | History of Cognitive function |
| 11334-0 | History of Growth+Development Narrative |
| 11335-7 | History of Growth+Development |
| 11336-5 | History of Hospitalization Narrative |
| 11337-3 | History of Hospitalization |
| 11338-1 | History of Major illnesses and injuries Narrative |
| 11339-9 | History of Major illnesses and injuries |
| 11340-7 | History of Occupation Narrative |
| 11341-5 | History of Occupation |
| 11342-3 | History of Other nonmedical drug use Narrative |
| 11343-1 | History of Other nonmedical drug use |
| 11344-9 | History of Other social factors Narrative |
| 11345-6 | History of Other social factors |
| 11346-4 | History of Outpatient visits Narrative |
| 11347-2 | History of Outpatient visits |
| 11348-0 | History of Past illness Narrative |
| 11349-8 | History of Past illness |
| 11350-6 | History of Sexual behavior Narrative |
| 11351-4 | History of Sexual behavior |
| 11366-2 | History of Tobacco use Narrative |
| 11367-0 | History of Tobacco use |
| 11368-8 | Illness or injury onset date and time |
| 11369-6 | History of Immunization Narrative |
| 11370-4 | Immunization status - Reported |
| 11371-2 | Initial visit for chief complaint |
| 11372-0 | Injury associated activity |
| 11373-8 | Injury cause |
| 11374-6 | Injury incident description Narrative |
| 11375-3 | Injury intent |
| 11376-1 | Injury location |
| 11380-3 | Marital status and living arrangements Narrative - Reported |
| 11381-1 | Marital status and living arrangements - Reported |
| 11382-9 | Medication allergy - Reported |
| 11383-7 | Patient problem outcome Narrative |
| 11384-5 | Physical examination by organ systems |
| 11449-6 | Pregnancy status - Reported |
| 11450-4 | Problem list - Reported |
| 11451-2 | Psychiatric findings Narrative |
| 11452-0 | Psychiatric findings |
| 11454-6 | Responsiveness assessment at First encounter |
| 11457-9 | Safety equipment used |
| 11458-7 | Clostridium tetani immunization status |
| 11493-4 | Hospital discharge studies summary Narrative |
| 11514-7 | Chiropractic Episode of care medical records |
| 11515-4 | Physical therapy Episode of care medical records |
| 11516-2 | Physician Episode of care medical records |
| 11517-0 | Podiatry Episode of care medical records |
| 11518-8 | Psychology Episode of care medical records |
| 11519-6 | Social service Episode of care medical records |
| 11520-4 | Speech therapy Episode of care medical records |
| 11521-2 | Occupational therapy Episode of care medical records |
| 11535-2 | Hospital discharge Dx Narrative |
| 11544-4 | Hospital discharge follow-up Narrative |
| 11612-9 | [#] Abortions |
| 11613-7 | [#] Abortions.induced |
| 11614-5 | [#] Abortions.spontaneous |
| 11636-8 | [#] Births.live |
| 11637-6 | [#] Births.preterm |
| 11638-4 | [#] Births.still living |
| 11639-2 | [#] Births.term |
| 11640-0 | [#] Births total |
| 11767-1 | Body weight percentile Comparison of estimated fetal weight with standard population distribution at same estimated gestational age |
| 11769-7 | Body weight percentile range Categorization by comparison with standards |
| 11778-8 | Delivery date Estimated |
| 11779-6 | Delivery date Estimated from last menstrual period |
| 11780-4 | Delivery date Estimated from ovulation date |
| 11781-2 | Delivery date US composite estimate |
| 11870-3 | Examination level ultrasound |
| 11878-6 | Number of fetuses by US |
| 11976-8 | Ovulation date |
| 11977-6 | [#] Parity |
| 11996-6 | [#] Pregnancies |
| 12008-9 | Pulsatility index US.doppler |
| 12010-5 | R-R duration US |
| 12023-8 | Resistivity index US.doppler |
| 12131-9 | [Interpretation] Study observation general US |
| 12132-7 | Narrative [Interpretation] Study observation general US |
| 12144-2 | Systolic flow/Diastolic flow US.doppler |
| 12156-6 | Transducer site |
| 12157-4 | Ultrasonographer gravidity number |
| 12159-0 | Ultrasound scan quality |
| 15334-6 | Challenge |
| 18589-2 | Admitted at destination facility |
| 19775-6 | Relevant Hx and Px for procedure Narrative Endoscopy |
| 19776-4 | Relevant Hx and Px for procedure Endoscopy |
| 19777-2 | Indications Endoscopy |
| 19778-0 | Indications description Narrative Endoscopy |
| 19789-7 | Medications [Identifier] |
| 19790-5 | Medication administration Narrative |
| 19817-6 | Complications |
| 19819-2 | Post GI procedure instructions [Instructions] Narrative |
| 19820-0 | Return visit post GI procedure [Instructions] Narrative |
| 19821-8 | Return visit post GI procedure [Date and time] |
| 19822-6 | Return visit clinic post GI procedure [Location] Narrative |
| 19823-4 | Return visit post GI procedure [Telephone number] |
| 19824-2 | Return visit conditions |
| 19826-7 | Informed consent obtained |
| 21833-9 | Alternate census tract at cancer diagnosis |
| 21837-0 | Hispanic origin Best estimate |
| 21838-8 | Ethnicity Computed |
| 21840-4 | Sex [NAACCR v.11] |
| 21842-0 | Birthplace |
| 21843-8 | History of Usual occupation |
| 21844-6 | History of Usual industry |
| 21847-9 | Usual occupation Narrative |
| 21848-7 | Usual industry Narrative |
| 21851-1 | Address at cancer diagnosis |
| 21866-9 | Patient ID.hospital |
| 21975-8 | Date last contact |
| 21979-0 | Planned/next follow-up |
| 21980-8 | Other follow-up method Narrative |
| 21986-5 | Autopsy status |
| 21987-3 | Geographic place of death |
| 22017-8 | State defined narrative Narrative |
| 22018-6 | Military patient number |
| 22019-4 | Death certificate number |
| 22020-2 | Maiden name |
| 22025-1 | Physician managing [Identifier] |
| 22026-9 | Physician follow up [Identifier] |
| 22027-7 | Surgeon primary [Identifier] |
| 22028-5 | Physician [Identifier] |
| 22029-3 | Physical exam Narrative |
| 22030-1 | Xray/Scan.total Narrative |
| 22031-9 | Scopic exam Narrative |
| 22032-7 | Lab tests Narrative |
| 22033-5 | Operations (?).total Narrative |
| 29298-7 | Reason for visit |
| 29299-5 | Reason for visit Narrative |
| 29300-1 | Procedure type |
| 29303-5 | Medication administered |
| 29304-3 | Medication dispensed |
| 29305-0 | Medication prescribed |
| 29306-8 | Surgery procedure |
| 29308-4 | Diagnosis |
| 29463-7 | Body weight |
| 29544-4 | Physical findings |
| 29545-1 | Physical findings Narrative |
| 29546-9 | History of disorders Narrative |
| 29547-7 | History of Symptoms and diseases |
| 29548-5 | Diagnosis Narrative |
| 29549-3 | Medication administered Narrative |
| 29550-1 | Medication dispensed Narrative |
| 29551-9 | Medication prescribed Narrative |
| 29554-3 | Procedure Narrative |
| 29555-0 | Milk production [Mass/time] 24 hour |
| 29762-2 | Social history Narrative |
| 29768-9 | Date vaccine information statement published |
| 29769-7 | Date vaccine information statement presented |
| 30936-9 | Corynebacterium diphtheriae+Clostridium tetani+Bordetella pertussis dose count in combination vaccine |
| 30937-7 | Hepatitis B virus dose count in combination vaccine |
| 30938-5 | Haemophilus influenzae B dose count in combination vaccine |
| 30939-3 | Measles virus dose count in combination vaccine |
| 30940-1 | Measles virus+Mumps virus+Rubella virus dose count in combination vaccine |
| 30941-9 | Mumps virus dose count in combination vaccine |
| 30942-7 | Rubella virus dose count in combination vaccine |
| 30943-5 | Varicella zoster virus dose count in combination vaccine |
| 30944-3 | Date of vaccination temporary contraindication/precaution expiration |
| 30945-0 | Vaccination contraindication/precaution |
| 30946-8 | Date.vaccination contraindication/precaution effective |
| 30948-4 | Vaccination adverse event Narrative |
| 30949-2 | Vaccination adverse event outcome VAERS |
| 30950-0 | Number of days hospitalized due to vaccination adverse event |
| 30951-8 | Patient recovered VAERS |
| 30952-6 | Date and time of vaccination |
| 30953-4 | Date and time of onset of vaccination adverse event |
| 30954-2 | Relevant diagnostic tests/laboratory data Narrative |
| 30960-9 | Number of previous doses |
| 30961-7 | Other vaccines given within 4 weeks prior to vaccination that caused adverse reaction [Complex] Set |
| 30962-5 | Vaccinated at VAERS |
| 30963-3 | Funds vaccine purchased with VAERS |
| 30964-1 | Other medications |
| 30965-8 | Illness at time of vaccination |
| 30966-6 | Pre-existing physician-diagnosed allergies, birth defects, medical conditions |
| 30967-4 | Adverse event previously reported VAERS |
| 30968-2 | Adverse event following prior vaccination in patient [Complex] Set |
| 30971-6 | Adverse event VAERS |
| 30972-4 | Age at onset of adverse event |
| 30973-2 | Dose number |
| 30974-0 | Number of brothers and sisters |
| 30979-9 | Vaccines due next [Complex] Set |
| 30980-7 | Date vaccine due |
| 30981-5 | Earliest date to give |
| 30982-3 | Reason applied by forecast logic to project this vaccine |
| 31035-9 | Date of other vaccinations given within 4 weeks prior to the date of vaccine causing adverse event |
| 31044-1 | Immunization reaction |
| 31210-8 | Vital status NAACCR |
| 3137-7 | Body height Measured |
| 3138-5 | Body height Stated |
| 3139-3 | Body surface area Measured |
| 3140-1 | Body surface area Derived from formula |
| 3141-9 | Body weight Measured |
| 3142-7 | Body weight Stated |
| 3143-5 | Donor relation to patient |
| 3144-3 | Last menstrual period duration |
| 3146-8 | Menstrual status |
| 3172-4 | Time --post exercise |
| 32395-6 | Infant monitor type |
| 32396-4 | Labor duration |
| 32398-0 | Secondary male genitalia development |
| 32399-8 | Maternal risk factors |
| 32400-4 | Menses finding |
| 32401-2 | 10 minute Apgar Color |
| 32402-0 | 10 minute Apgar Heart rate |
| 32403-8 | 10 minute Apgar Muscle tone |
| 32404-6 | 10 minute Apgar Reflex irritability |
| 32405-3 | 10 minute Apgar Respiratory effort |
| 32406-1 | 1 minute Apgar Color |
| 32407-9 | 1 minute Apgar Heart rate |
| 32408-7 | 1 minute Apgar Muscle tone |
| 32409-5 | 1 minute Apgar Reflex irritability |
| 32410-3 | 1 minute Apgar Respiratory effort |
| 32411-1 | 5 minute Apgar Color |
| 32412-9 | 5 minute Apgar Heart rate |
| 32413-7 | 5 minute Apgar Muscle tone |
| 32414-5 | 5 minute Apgar Reflex irritability |
| 32415-2 | 5 minute Apgar Respiratory effort |
| 32416-0 | Newborn complication |
| 32417-8 | Newborn ICU admission diagnosis |
| 32418-6 | Obstetric trimester Stated |
| 32419-4 | Pain quality |
| 32490-5 | Tocolysis method |
| 32544-9 | Fat intake 72 hour |
| 32624-9 | Race |
| 32879-9 | Noncompliance with dental treatment |
| 32880-7 | History of Dental procedure |
| 32882-3 | Reason for dental evaluation |
| 32883-1 | Dental arch [Identifier] |
| 32964-9 | Dental prognosis Best estimate |
| 32970-6 | Eruption XR |
| 32973-0 | Exfoliation XR |
| 33065-4 | [#] Ectopic pregnancy |
| 33066-2 | Last menstrual period Estimated from EDD |
| 33067-0 | Conception date |
| 33435-9 | Inspiratory breath [Time] --on ventilator |
| 33438-3 | Breath rate mechanical --on ventilator |
| 33450-8 | Ventilator adverse event |
| 33555-4 | Inactivated poliovirus vaccine dose count in combination vaccine |
| 34011-7 | Previous dental surgery |
| 34012-5 | Previous dental appliance wear |
| 34025-7 | Previous dental prosthesis wear |
| 34044-8 | Magnification instrument |
| 34045-5 | Oral evaluation exam |
| 34048-9 | Dental material used/Proposed |
| 34536-3 | Fluid intake and output panel 24 hour |
| 34537-1 | Fluid intake and output panel 8 hour |
| 34552-0 | 2D echocardiogram panel |
| 34565-2 | Vital signs, weight and height panel |
| 34566-0 | Vital signs with method details panel |
| 35088-4 | Glasgow coma scale |
| 35089-2 | History and physical panel |
| 35090-0 | Patient history |
| 35091-8 | Patient physical |
| 35092-6 | Urology testicular ultrasound |
| 35093-4 | Urology urinary tract ultrasound |
| 35094-2 | Blood pressure panel |
| 35095-9 | Body temperature panel |
| 35096-7 | OB ultrasound panel |
| 35264-1 | Calcium intake 24 hour |
| 35350-8 | NAACCR survival to last contact (in months) [Time] |
| 35658-4 | Tumor survival (in months) [Time] |
| 35659-2 | Age at specimen collection |
| 38201-0 | Pain onset [Date and time] - Reported |
| 38202-8 | Pain onset.hours ago - Reported |
| 38203-6 | Speed of pain onset - Reported |
| 38206-9 | Pain temporal pattern - Reported |
| 38207-7 | Pain duration - Reported |
| 38208-5 | Pain severity - Reported |
| 38209-3 | Pain exacerbating factors - Reported |
| 38210-1 | Pain alleviating factors - Reported |
| 38211-9 | Pain initiating event Narrative - Reported |
| 38212-7 | Pain assessment panel |
| 38213-5 | FLACC pain assessment panel |
| 38214-3 | Pain severity [Score] Visual analog score |
| 38215-0 | Pain severity total [Score] FLACC |
| 38216-8 | Pain severity Face FLACC |
| 38217-6 | Pain severity Legs FLACC |
| 38218-4 | Pain severity Activity FLACC |
| 38219-2 | Pain severity Cry FLACC |
| 38220-0 | Pain severity Consolability FLACC |
| 38221-8 | Pain severity Wong-Baker FACES pain rating scale |
| 38223-4 | Physical Activity Braden Scale |
| 38224-2 | Physical mobility Braden Scale |
| 38225-9 | Nutrition Intake Pattern Braden Scale |
| 38227-5 | Braden Scale Total Score |
| 38228-3 | Braden scale skin assessment panel |
| 38876-9 | Respiratory contraindications to elevating head of bed greater than 30 degrees |
| 38877-7 | Oral care given |
| 38878-5 | Ventilator mode change reason |
| 38879-3 | Ventilator disconnect reason |
| 38880-1 | Ventilator alarm reason |
| 38881-9 | Emotional stability behavior --pre event |
| 38882-7 | Emotional stability behavior --post event |
| 38883-5 | Reintubated urgency |
| 38885-0 | Extubation Urgency |
| 38999-9 | Hospital discharge DRG [Interpretation] |
| 39108-6 | Body hair distribution [Interpretation] |
| 39111-0 | Body site |
| 39112-8 | Body location qualifier |
| 39135-9 | Wound assessment panel |
| 39137-5 | Oral assessment panel |
| 39156-5 | Body mass index (BMI) [Ratio] |
| 39810-7 | RuralUrban continuum 1993 |
| 41291-6 | History of Immunization |
| 41359-1 | Active range of motion panel Quantitative |
| 41360-9 | Passive range of motion panel Quantitative |
| 41904-4 | Blood pressure measurement site |
| 41905-1 | Altitude |
| 41950-7 | Number of steps in 24 hour Measured |
| 41951-5 | Number of steps in 24 hour mean Measured |
| 41952-3 | Number of steps in 1 week Measured |
| 41953-1 | Distance walked in 24 hour Calculated |
| 41954-9 | Distance walked in 24 hour mean Calculated |
| 41955-6 | Distance walked in 1 week Calculated |
| 41956-4 | Walking speed 24 hour maximum Calculated |
| 41957-2 | Walking speed 24 hour mean Calculated |
| 41958-0 | Walking speed in the past week maximum Calculated |
| 41959-8 | Walking speed in the past week mean Calculated |
| 41971-3 | Total metabolism [Mass] 24 hour |
| 41979-6 | Calories burned in 24 hour Calculated |
| 41980-4 | Calories burned in 1 week Calculated |
| 41981-2 | Calories burned |
| 41982-0 | Percentage of body fat Measured |
| 42022-4 | NAACCR hospital tumor registration.permanent [Identifier] |
| 42024-0 | NAACCR hispanic identification algorithm hispanic origin Derived |
| 42025-7 | NAACCR Indian Health Service linkage |
| 42033-1 | Number of tumors and histologies |
| 42077-8 | Patient phone number |
| 42078-6 | Follow-up contact supplemental information |
| 42107-3 | Comorbidities and complications 2 |
| 42108-1 | Comorbidities and complications 3 |
| 42109-9 | Comorbidities and complications 4 |
| 42110-7 | Comorbidities and complications 5 |
| 42111-5 | Comorbidities and complications 6 |
| 42112-3 | Comorbidities and complications 7 |
| 42113-1 | Comorbidities and complications 8 |
| 42114-9 | Comorbidities and complications 9 |
| 42115-6 | Comorbidities and complications 10 |
| 42125-5 | RuralUrban continuum 2000 |
| 42126-3 | Comorbidities and complications 1 |
| 42127-1 | Name of follow-up contact |
| 42540-5 | Contributing Factor environment MERSTH |
| 42541-3 | Contributing Factor patient-related MERSTH |
| 42542-1 | Contributing Factor staff-related MERSTH |
| 42543-9 | Contributing Factor delay/Premature MERSTH |
| 42544-7 | Contributing Factor other Narrative MERSTH |
| 42545-4 | Event Outcome MERSTH |
| 42546-2 | Event Battery.MERS-TH MERSTH |
| 42547-0 | Event MERSTH |
| 42548-8 | Service MERSTH |
| 42549-6 | Event Type MERSTH |
| 42550-4 | Event description medication MERSTH |
| 42551-2 | Event description procedure/treatment/surgery MERSTH |
| 42552-0 | Event description food/nutrition MERSTH |
| 42553-8 | Event description fall MERSTH |
| 42554-6 | Event description accident MERSTH |
| 42555-3 | Event Description general nursing care MERSTH |
| 42556-1 | Event description equipment/device MERSTH |
| 42557-9 | Event description laboratory MERSTH |
| 42558-7 | Event description transfusion service MERSTH |
| 42559-5 | Event description administrative MERSTH |
| 42560-3 | Event description complaint MERSTH |
| 42561-1 | Event description environmental hazard/safety MERSTH |
| 42562-9 | Event description crime/intentional harm/Patient disappearance MERSTH |
| 42563-7 | Event description adverse event MERSTH |
| 42564-5 | Contributing Factor technical MERSTH |
| 42565-2 | Contributing Factor organization MERSTH |
| 42566-0 | Contributing Factor communication/Documentation MERSTH |
| 42784-9 | Ethnic Background Stated |
| 43142-9 | Height measurement device panel |
| 43143-7 | Weighing device panel |
| 43144-5 | Pedometer device panel |
| 43145-2 | Peak flow meter device panel |
| 43146-0 | Oxygen saturation device panel |
| 43147-8 | Metabolism measurement device panel |
| 43148-6 | Insulin delivery device panel |
| 43149-4 | Heart rate device panel |
| 43150-2 | Hemoglobin A1c measurement device panel |
| 43151-0 | Glucose meter device panel |
| 43152-8 | Blood pressure device panel |
| 43153-6 | Blood coagulation device panel |
| 43993-5 | Age at delivery |
| 44100-6 | Medical problem |
| 44756-5 | Reason for transplant |
| 44758-1 | Transplant risk factors |
| 44760-7 | Model for end-stage liver disease score |
| 44763-1 | Native inferior vena cava liver graft attachment |
| 44764-9 | Biliary anastomosis procedure |
| 44767-2 | Relationship of subject to patient |
| 44833-2 | Preliminary diagnosis |
| 44939-7 | History of Adverse drug reaction Narrative |
| 44940-5 | Alcoholic drinks per week - Reported |
| 44941-3 | Barriers to self management |
| 44943-9 | Self management |
| 44944-7 | Other alert |
| 44965-2 | Jugular vein distention --head raised 30 degrees |
| 44966-0 | Edema |
| 44967-8 | Electrocardiograph lead |
| 45033-8 | Cardiovascular physiologic and EKG assessment panel |
| 45230-0 | District where patient entered HIV treatment |
| 45231-8 | HIV treatment prior to enrollment |
| 45232-6 | Reason medically eligible for HIV treatment |
| 45233-4 | World Health Organization HIV stage |
| 45234-2 | Date eligible and selected to start HIV treatment |
| 45235-9 | Date original clinic HIV treatment start |
| 45236-7 | HIV treatment cohort |
| 45237-5 | Date lost to HIV treatment follow-up |
| 45238-3 | Date lost to HIV treatment therapy |
| 45239-1 | Current HIV treatment therapy duration |
| 45240-9 | Isoniazid therapy start date |
| 45241-7 | Tuberculosis status |
| 45242-5 | Tuberculosis treatment start date |
| 45243-3 | Reason for discontinuation of anti-infective phrophylaxis medication |
| 45244-1 | Percent HIV ART medication dose number taken/Medication dose number prescribed - Reported |
| 45245-8 | Degree of adherence to co-trimoxazole |
| 45246-6 | Degree of adherence to anti-retroviral drug regimen |
| 45247-4 | Reason for missing HIV treatment administration schedule |
| 45248-2 | Number of Number of hospital days since last outpatient visit - Reported |
| 45249-0 | Evidence of tuberculosis resistance |
| 45257-3 | Date dropped from HIV treatment |
| 45258-1 | Percent HIV ART medication dose number taken/Medication dose number prescribed MEMS cap |
| 45259-9 | Percent HIV ART actual prescription fills number/Ideal prescription fills number |
| 45260-7 | HIV ART medication |
| 45261-5 | Number of HIV antiretroviral medication doses missed yesterday ACTG |
| 45262-3 | Number of HIV antiretroviral medication doses missed 2 days ago ACTG |
| 45263-1 | Number of HIV antiretroviral medication doses missed 3 days ago ACTG |
| 45264-9 | Number of HIV antiretroviral medication doses missed 4 days ago ACTG |
| 45354-8 | Date Next Dose |
| 45371-2 | Multiple Pregnancy |
| 45392-8 | First name |
| 45393-6 | Middle initial |
| 45394-4 | Last name |
| 45395-1 | Name suffix |
| 45396-9 | Social Security number [Identifier] |
| 45397-7 | Medicare or comparable number |
| 45400-9 | Medicaid number |
| 45401-7 | Postal code [Location] |
| 45403-3 | Room number [Location] |
| 45404-1 | Marital status |
| 46098-0 | Sex |
| 46106-1 | Medical record number [Identifier] |
| 46239-0 | Chief complaint+Reason for visit Narrative |
| 46240-8 | History of Hospitalizations+Outpatient visits Narrative |
| 46241-6 | Hospital admission diagnosis Narrative - Reported |
| 46249-9 | Vaccination take-response type |
| 46250-7 | Vaccination take-response date |
| 46251-5 | Age group |
| 46438-8 | Cancer identification section Set NAACCR v.11 |
| 46439-6 | Demographic section Set NAACCR v.11 |
| 46440-4 | Edit overrides/Conversion history/System admin section Set NAACCR v.11 |
| 46441-2 | Follow-up/Recurrence/Death section Set NAACCR v.11 |
| 46442-0 | Hospital-confidential section Set NAACCR v.11 |
| 46443-8 | Hospital-specific section Set NAACCR v.11 |
| 46444-6 | Other-confidential section Set NAACCR v.11 |
| 46445-3 | Patient-confidential section Set NAACCR v.11 |
| 46446-1 | Record ID section Set NAACCR v.11 |
| 46447-9 | Special use section Set NAACCR v.11 |
| 46448-7 | Stage/prognostic factors section Set NAACCR v.11 |
| 46449-5 | Text-diagnosis section Set NAACCR v.11 |
| 46450-3 | Text-miscellaneous section Set NAACCR v.11 |
| 46451-1 | Text-treatment section Set NAACCR v.11 |
| 46452-9 | Treatment-1st course section Set NAACCR v.11 |
| 46453-7 | Treatment-subsequent and other section Set NAACCR v.11 |
| 46499-0 | State of residence |
| 47224-1 | In vitro fertilization pregnancy |
| 47239-9 | Reason for stopping HIV treatment |
| 47240-7 | Date determined medically eligible to start HIV treatment |
| 47241-5 | Date determined medically eligible and ready to start HIV treatment |
| 47242-3 | Medication or other side effects associated with HIV treatment |
| 47243-1 | Severity of side effect to HIV treatment |
| 47244-9 | Symptom, diagnosis, or opportunistic infection related to HIV treatment |
| 47246-4 | HIV Antiretroviral therapy Demographic information section |
| 47247-2 | HIV Antiretroviral therapy Outpatient encounter-level information section |
| 47248-0 | HIV Antiretroviral therapy Antiretroviral therapy status section |
| 47249-8 | HIV Antiretroviral therapy HIV care and family status section |
| 48332-1 | 10 minute Apgar panel |
| 48333-9 | 5 minute Apgar panel |
| 48334-7 | 1 minute Apgar panel |
| 48765-2 | Allergies and adverse reactions Document |
| 48768-6 | Payment sources Document |
| 48769-4 | Continuity of Care panel |
| 49033-4 | Menstrual History - Reported |
| 49053-2 | History of Neural tube defect Narrative |
| 49083-9 | North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 11 panel |
| 49084-7 | Census block group 1970and80and90 |
| 49088-8 | Sonographer name |
| 49089-6 | Sonographer [Identifier] |
| 49143-1 | North American Association of Central Cancer Registries, Inc (NAACCR, Inc) Pathology Laboratory Electronic Reporting panel |
| 49560-6 | Payment procedure |
| 49561-4 | Payment diagnosis [identifier] |
| 50064-5 | Ideal body weight |
| 50400-1 | Body temperature --after transfusion reaction |
| 50715-2 | History of Trisomy 21 Narrative |
| 52455-3 | Admission date |
| 52462-9 | Nickname |
| 52463-7 | Patient Identification Number or Provider Account Number |
| 52525-3 | Discharge date |
| 52539-4 | Prior postal code [Location] |
| 52797-8 | Diagnosis ICD code [Identifier] |
| 53626-8 | CT Cerebral atrophic index |
| 53661-5 | Reliability of last menstrual period observation |
| 53662-3 | Conception method |
| 53663-1 | Date of prior gestational age estimate |
| 53664-9 | Method of prior gestational age estimate |
| 53665-6 | Date of best overall gestational age estimate |
| 53666-4 | Method of best overall gestational age estimate |
| 53692-0 | Delivery date Estimated from conception date |
| 53694-6 | Delivery date Estimated from prior gestational age assessment |
| 53719-1 | Date of death - Canada |
| 53720-9 | Race NAPIIA |
| 53756-3 | Respiratory status finding |
| 53826-4 | History of Trisomy 21 Qualitative |
| 53827-2 | History of Neural tube defect Qualitative |
| 54111-0 | Newborn hearing screening panel |
| 54588-9 | Interpreter needed |
| 54899-0 | Preferred language |
| 55102-8 | Surgical operation note disposition Narrative |
| 55103-6 | Surgical operation note estimated blood loss Narrative |
| 55104-4 | Surgical operation note planned procedure Narrative |
| 55107-7 | Addendum Document |
| 55108-5 | Clinical presentation Document |
| 55109-3 | Complications Document |
| 55110-1 | Conclusions [Interpretation] Document |
| 55111-9 | Current imaging procedure descriptions Document |
| 55112-7 | Document summary |
| 55113-5 | Key images Document Radiology |
| 55114-3 | Prior imaging procedure descriptions Document |
| 55115-0 | Requested imaging studies information Document |
| 55122-6 | Surgical operation note implants Narrative |
| 55140-8 | Vaccine Adverse Event Reporting System (VAERS) panel |
| 55168-9 | Data Elements for Emergency Department Systems (DEEDS) Release 1.1 |
| 55169-7 | Data Elements for Emergency Department Systems (DEEDS) Release 1.0 |
| 55172-1 | ED procedures and results Set DEEDS |
| 55173-9 | ED disposition and diagnosis data Set DEEDS |
| 55174-7 | Patient identification data Set DEEDS |
| 55175-4 | Facility and Practitioner identification data Set DEEDS |
| 55176-2 | ED arrival and first assessment data at First encounter Set DEEDS |
| 55177-0 | ED History and Physical Examination Data Set DEEDS |
| 55209-1 | Date and time of most recent arrival in U.S. |
| 55210-9 | Geotemporal history |
| 55211-7 | Shared razor, toothbrushes or nail care items |
| 55212-5 | Occupation related direct blood or body fluid exposure frequency |
| 55213-3 | Number of male sexual partners in 6 months before symptom onset |
| 55214-1 | Number of female sexual partners in 6 months before symptom onset |
| 55215-8 | Total number of lifetime sexual partners |
| 55216-6 | Physical assault on exposed person involving blood or semen |
| 55217-4 | Stick or puncture with a needle or other object contaminated with blood |
| 55218-2 | Date of actual exposure to blood/body fluid |
| 55256-2 | ED payment data Set DEEDS |
| 55257-0 | Date of last Clostridium tetani immunization |
| 55258-8 | Problem alleviating factors Narrative |
| 55259-6 | Time last ate solid food |
| 55260-4 | Time last drank liquid |
| 55261-2 | Rabies virus immunization status |
| 55262-0 | Influenza virus immunization status |
| 55263-8 | Bordetella pertussis immunization status |
| 55264-6 | Hepatitis A virus immunization status |
| 55265-3 | Measles virus status |
| 55266-1 | Haemophilus influenzae B immunization status |
| 55267-9 | Human papilloma virus immunization status |
| 55268-7 | Rotavirus immunization status |
| 55269-5 | Neisseria meningitidis immunization status |
| 55270-3 | Streptococcus pneumoniae polyvalent immunization status |
| 55271-1 | Streptococcus pneumoniae conjugated immunization status |
| 55272-9 | Corynebacterium diphtheriae immunization status |
| 55273-7 | Polio virus immunization status |
| 55274-5 | Varicella zoster virus status |
| 55275-2 | Hepatitis B virus status |
| 55276-0 | Hepatitis C virus status |
| 55277-8 | HIV status |
| 55278-6 | Rubella virus status |
| 55279-4 | Cytomegalovirus status |
| 55280-2 | Military service Narrative |
| 55281-0 | Number of fetuses |
| 55282-8 | Date symptoms of pregnancy first noted |
| 55285-1 | Glasgow coma score special circumstances |
| 55286-9 | Physical exam by body areas |
| 55288-5 | ED medication data Set DEEDS |
| 55399-0 | Diabetes tracking panel |
| 55400-6 | Date of last eye examination |
| 55403-0 | Asthma tracking panel |
| 55404-8 | Asthma spells per week |
| 55405-5 | Heart failure tracking panel |
| 55408-9 | Exercise tolerance |
| 55409-7 | Exercise tracking panel |
| 55411-3 | Exercise duration |
| 55412-1 | Exercise distance |
| 55413-9 | Pedometer tracking panel |
| 55414-7 | Seizures per month |
| 55415-4 | Oxygen therapy tracking panel |
| 55416-2 | Oxymetry special circumstances |
| 55417-0 | Short blood pressure panel |
| 55418-8 | Weight and Height tracking panel |
| 55421-2 | Calories burned Machine estimate |
| 55423-8 | Number of steps in unspecified time Pedometer |
| 55424-6 | Calories burned in unspecified time Pedometer |
| 55427-9 | Seizure disorder tracking panel |
| 55430-3 | Distance walked in unspecified time Pedometer |
| 55752-0 | Clinical information |
| 55753-8 | Treatment information |
| 56051-6 | Hispanic or Latino |
| 56056-5 | Birth weight - Reported |
| 56092-0 | Birth weight GNWCH |
| 56093-8 | Birth weight NVSS |
| 56097-9 | Hand dominance - drawing [ALSPAC] |
| 56098-7 | Hand dominance - throwing a ball [ALSPAC] |
| 56099-5 | Hand dominance - coloring [ALSPAC] |
| 56100-1 | Hand dominance - holding a toothbrush [ALSPAC] |
| 56162-1 | Hand dominance - 42 months [Interpretation] [ALSPAC] |
| 56444-3 | Healthcare communication Document |
| 56445-0 | Medication summary Document |
| 56446-8 | Appointment summary Document |
| 56794-1 | Internal identifier |
| 56795-8 | Account number [Identifier] |
| 56797-4 | Episode unique identifier |
| 56798-2 | Alias |
| 56799-0 | Address |
| 56800-6 | Date and time ED consult request initiated |
| 56801-4 | Date and time ED consult starts |
| 56813-9 | Individuals accompanying patient to ED |
| 56814-7 | Prehospital care |
| 56815-4 | Time placed into treatment area |
| 56816-2 | Patient location |
| 56817-0 | Presenting problem |
| 56818-8 | Problem description [Identifier] |
| 56819-6 | Problem prior evaluation |
| 56820-4 | Problem context |
| 56821-2 | Problem exacerbating factors |
| 56822-0 | Problem response to therapy |
| 56823-8 | Problem quality or description |
| 56824-6 | Problem location |
| 56825-3 | Problem time course |
| 56826-1 | Problem frequency |
| 56827-9 | Symptom duration during occurrences or episodes |
| 56828-7 | Time contractions became regular |
| 56829-5 | Time membranes ruptured |
| 56830-3 | Limitations in obtaining history |
| 56831-1 | Problem associated signs and symptoms |
| 56832-9 | Type of substance abused |
| 56833-7 | Pregnancy related history Narrative |
| 56835-2 | Viability of current pregnancy Narrative |
| 56836-0 | History of Blood transfusion Narrative |
| 56837-8 | History of Neoplastic disease Narrative |
| 56838-6 | History of Infectious disease Narrative |
| 56839-4 | Acuity assessment Narrative |
| 56841-0 | Pain severity descriptive category |
| 56842-8 | Chronic pain assessment Narrative |
| 56845-1 | Pulse strength on exam Narrative |
| 56846-9 | Cardiac biomarkers (set) |
| 56847-7 | Calculated and derived values (set) |
| 56848-5 | Invasive hemodynamic monitoring (set) |
| 56849-3 | Cardiac rhythm monitoring (set) |
| 56850-1 | Interpretation and review of laboratory results |
| 56851-9 | Care process or plan |
| 56852-7 | Amount of ED discharge medication to be dispensed |
| 56853-5 | ED outcome |
| 56857-6 | Time accepted for admission or transfer |
| 56858-4 | Time received by accepting facility or unit |
| 56859-2 | Date and time of ED departure |
| 56860-0 | ED follow-up care assistance |
| 56865-9 | Problem diagnostic considerations |
| 56866-7 | Onset of painful contractions |
| 56868-3 | ED procedure indication [Interpretation] |
| 56869-1 | Continuous ST segment monitoring (set) |
| 56872-5 | Constitutional symptoms Narrative |
| 56874-1 | Serology and blood bank studies (set) |
| 56875-8 | Mixed venous oxygen saturation monitoring (set) |
| 57016-8 | Privacy policy acknowledgment Document |
| 57024-2 | Health Quality Measure document |
| 57025-9 | Data criteria Narrative |
| 57026-7 | Population criteria Narrative |
| 57027-5 | Measure observations Narrative |
| 57059-8 | Pregnancy visit summary note Narrative |
| 57060-6 | Estimated date of delivery Narrative |
| 57061-4 | Antepartum flowsheet panel Narrative |
| 57062-2 | [#] Births.stillborn |
| 57063-0 | Delivery date Estimated from quickening date |
| 57064-8 | Delivery date Estimated from date fundal height reaches umb |
| 57065-5 | Quickening date |
| 57066-3 | Date fundal height reaches umbilicus |
| 57069-7 | Preterm labor symptoms |
| 57070-5 | Date next clinic visit |
| 57071-3 | Obstetric delivery method |
| 57072-1 | Intravenous fluids administered Narrative |
| 57073-9 | Prenatal records |
| 57074-7 | Labor and delivery process Narrative |
| 57076-2 | Postpartum hospitalization treatment Narrative |
| 57078-8 | Antenatal testing and surveillance Narrative |
| 57079-6 | Birth plan Narrative |
| 57080-4 | Implanted medical device Narrative |
| 57081-2 | Anesthesia risk review of systems Narrative |
| 57082-0 | Antepartum record panel |
| 57083-8 | Labor and Delivery record panel |
| 57696-7 | Pain severity FPS-R |
| 57713-0 | Infant factors that affect newborn screening interpretation |
| 57714-8 | Obstetric estimation of gestational age |
| 57715-5 | Birth time |
| 57826-0 | Co-payment amount Narrative |
| 57827-8 | Reason for co-payment exemption Document |
| 57830-2 | Admission request Document |
| 57834-4 | Patient transportation request Document |
| 57849-2 | Medication allergy Narrative - Reported |
| 57852-6 | Problem list Narrative - Reported |
| 58131-4 | Date of influenza vaccination |
| 58229-6 | Body weight Measured --when specimen taken |
| 58232-0 | Hearing loss risk indicators [Identifier] |
| 58477-1 | Pulmonary function report |
| 59268-3 | Neonatal care report |
| 59270-9 | Surgical operative note panel |
| 59271-7 | Hospital discharge summary panel |
| 59362-4 | Race or ethnicity OMB.1997 |
| 59574-4 | Body mass index (BMI) [Percentile] |
| 59575-1 | Body mass index (BMI) [Percentile] Per age |
| 59576-9 | Body mass index (BMI) [Percentile] Per age and sex |
| 59768-2 | Procedure indications [Interpretation] Narrative |
| 59769-0 | Postprocedure diagnosis Narrative |
| 59770-8 | Procedure estimated blood loss Narrative |
| 59771-6 | Procedure implants Narrative |
| 59772-4 | Planned procedure Narrative |
| 59773-2 | Procedure specimens taken Narrative |
| 59774-0 | Procedure anesthesia Narrative |
| 59775-7 | Procedure disposition Narrative |
| 59776-5 | Procedure findings Narrative |
| 59777-3 | Latest date to give immunization |
| 59778-1 | Date when overdue for immunization |
| 59779-9 | Immunization schedule used |
| 59780-7 | Immunization series |
| 59781-5 | Dose validity |
| 59782-3 | Number of doses in primary immunization series |
| 59783-1 | Status in immunization series |
| 59784-9 | Disease with presumed immunity |
| 59785-6 | Indication for Immunization |
| 59852-4 | North American Association of Central Cancer Registries, Inc (NAACCR, Inc) version 12 panel |
| 60431-4 | Date of previous biopsy |
| 60432-2 | Date of previous PAP smear |
| 60484-3 | CDC Immunization panel |
| 60498-3 | Cancer identification section Set NAACCR v.12 |
| 60499-1 | Demographic section Set NAACCR v.12 |
| 60500-6 | Edit overrides/Conversion history/System admin section Set NAACCR v.12 |
| 60501-4 | Follow-up/Recurrence/Death section Set NAACCR v.12 |
| 60502-2 | Hospital-confidential section Set NAACCR v.12 |
| 60503-0 | Hospital-specific section Set NAACCR v.12 |
| 60504-8 | Other-confidential section Set NAACCR v.12 |
| 60505-5 | Patient-confidential section Set NAACCR v.12 |
| 60506-3 | Record ID section Set NAACCR v.12 |
| 60507-1 | Special use section Set NAACCR v.12 |
| 60508-9 | Stage/prognostic factors section Set NAACCR v.12 |
| 60509-7 | Text-diagnosis section Set NAACCR v.12 |
| 60510-5 | Text-miscellaneous section Set NAACCR v.12 |
| 60511-3 | Text-treatment section Set NAACCR v.12 |
| 60512-1 | Treatment-1st course section Set NAACCR v.12 |
| 60513-9 | Treatment-subsequent and other section Set NAACCR v.12 |
| 60516-2 | Hormone treatment |
| 60567-5 | Comprehensive pathology report panel |
| 60590-7 | Medication dispensed.brief Document |
| 60591-5 | Patient summary Document |
| 60592-3 | Patient summary.unexpected contact Document |
| 60593-1 | Medication dispensed.extended Document |
| 60824-0 | Oxygen delivery (VO2)/Body surface area [Volume Rate/Area] |
| 60842-2 | Oxygen consumption (VO2) |
| 61144-2 | Diet and nutrition Narrative |
| 61146-7 | Goals Narrative |
| 61147-5 | Expected outcomes Narrative |
| 61149-1 | Objective Narrative |
| 61150-9 | Subjective Narrative |
| 61356-2 | Medication pharmaceutical advice.extended Document |
| 61357-0 | Medication pharmaceutical advice.brief Document |
| 62317-3 | Date of last blood product transfusion |
| 62387-6 | Interventions Narrative |
| 63485-7 | Computer generated recommendation Document |
| 63503-7 | Marital status [NHANES] |
| 63504-5 | What is the highest grade or level of school you have completed or the highest degree you have received [NHANES] |
| 63575-5 | Was there ever a time when two or more of these problems occurred together [SSAGA II] |
| 63576-3 | At what age did you begin to drink regularly - that is, drinking at least once a month for 6 months or more [SSAGA II] |
| 63577-1 | How old were you the first time you got drunk, that is, your speech was slurred or you were unsteady on your feet [SSAGA II] |
| 63578-9 | In your lifetime, what is the largest number of drinks you have ever had in a 24 hour period, including all types of alcohol [SSAGA II] |
| 63579-7 | Have you ever taken a drink to keep from having any of these problems, or to make them go away [SSAGA II] |
| 63580-5 | Have you ever smoked part or all of a cigarette [PhenX] |
| 63581-3 | Have you smoked at least 100 cigarettes in your entire life [PhenX] |
| 63582-1 | Do you now smoke cigarettes every day, some days, or not at all [PhenX] |
| 63583-9 | Has there ever been a period in your life when you smoked cigarettes every day for at least 30 days [PhenX] |
| 63591-2 | What was the largest number of drinks that you ever drank in a single day [AUDADIS-IV] |
| 63592-0 | Did your tolerance to alcohol increase 50 percent or more [SSAGA II] |
| 63593-8 | Did the need to drink a lot more before you got drunk increase 50 percent or more [SSAGA II] |
| 63594-6 | Were you unable to stop or cut down drinking 3 or more times [SSAGA II] |
| 63595-3 | Did you ever start drinking and become drunk when you didn't want to 3 or more times [SSAGA II] |
| 63596-1 | Did giving up or greatly reduced important activities while drinking happen 3 or more times or for a month or more [SSAGA II] |
| 63597-9 | During the past 30 days, on how many days did you drink one or more drinks of an alcoholic beverage [PhenX] |
| 63598-7 | On the days that you drank during the past 30 days, how many drinks did you usually have each day [PhenX] |
| 63599-5 | Did you ever become tolerant to alcohol, that is, you drank a great deal more in order to get an effect, or found you could no longer get high on the amount you used to drink [SSAGA II] |
| 63600-1 | Have you ever started drinking at times you promised yourself that you wouldn't, or have you ever drunk more than you intended, for example, when you decided to drink 2 drinks and ended up drinking 4 or more [SSAGA II] |
| 63601-9 | Have you ever given up or greatly reduced important activities while drinking - like sports, work, or associating with friends or relatives [SSAGA II] |
| 63602-7 | Has there ever been a period of several days or more when you spent so much time drinking or recovering from the effects of alcohol that you had little time for anything else [SSAGA II] |
| 63604-3 | Did spending so much time drinking or recovering from the effects of alcohol that you had little time for anything else happen 3 or more times or for a month or more [SSAGA II] |
| 63605-0 | Health problem resulting from long stretches of drinking [SSAGA II] |
| 63606-8 | Which of these problems occurred together [SSAGA II] |
| 63607-6 | Did taking a drink to keep from having any of these problems, or to make them go away, happen 3 times or more [SSAGA II] |
| 63608-4 | How old were you the first time you smoked part or all of a cigarette [PhenX] |
| 63609-2 | How old were you when you first started smoking cigarettes every day [TUS-CPS] |
| 63610-0 | How old were you when you first started smoking cigarettes fairly regularly [TUS-CPS] |
| 63614-2 | Did you ever find you could drink a lot more before you got drunk [SSAGA II] |
| 63615-9 | Have you wanted to stop or cut down on drinking 3 or more times [SSAGA II] |
| 63616-7 | Have you ever tried to stop or cut down on drinking [SSAGA II] |
| 63617-5 | How many times were you unable to stop or cut down on drinking [SSAGA II] |
| 63618-3 | Have you ever started drinking and become drunk when you didn't want to [SSAGA II] |
| 63619-1 | Did drinking ever cause you to have any other physical health problems [SSAGA II] |
| 63620-9 | Did you continue to drink knowing that drinking caused you to have health problems [SSAGA II] |
| 63621-7 | Have you ever continued to drink when you knew you had any other serious physical illness or condition that might be made worse by drinking [SSAGA II] |
| 63622-5 | Did you continue to drink after you knew it caused you any of these problems [SSAGA II] |
| 63623-3 | Other physical health problems from drinking [SSAGA II] |
| 63624-1 | Did long stretches of drinking cause you to have this health problem [SSAGA II] |
| 63625-8 | Emotional or psychological problem related to drinking [SSAGA II] |
| 63626-6 | Has drinking ever caused you this emotional or psychological problem for more than 24 hours to the point that it interfered with your functioning or relationships [SSAGA II] |
| 63627-4 | When you stopped, cut down or went without drinking, did you ever experience this problem for most of the day for 2 days or longer [SSAGA II] |
| 63628-2 | Problem after cutting down or going without drinking [SSAGA II] |
| 63630-8 | How long has it been since you last smoked part or all of a cigarette [PhenX] |
| 63631-6 | How old were you the last time you smoked part or all of a cigarette [PhenX] |
| 63632-4 | About how long has it been since you completely quit smoking cigarettes [TUS-CPS] |
| 63633-2 | In your entire life, have you had at least 1 drink of any kind of alcohol, not counting small tastes or sips [AUDADIS-IV] |
| 63634-0 | About how old were you when you first started drinking, not counting small tastes or sips of alcohol [PhenX] |
| 63635-7 | Did drinking when you promised yourself that you wouldn't, or being drunk more than you intended happen 3 times or more [SSAGA II] |
| 63636-5 | How soon after you wake up do, or did, you smoke your first cigarette [FTND] |
| 63637-3 | Do, or did, you find it difficult to refrain from smoking in places where it is forbidden, such as in church, at the library, in a cinema, etc [FTND] |
| 63638-1 | Smoking status [FTND] |
| 63639-9 | Which cigarette would, or did, you hate most to give up [FTND] |
| 63640-7 | How many cigarettes per day do, or did, you smoke [FTND] |
| 63641-5 | Do, or did, you smoke more frequently during the first hours after waking than during the rest of the day [FTND] |
| 63642-3 | Do, or did, you smoke if you are so ill that you are in bed most of the day [FTND] |
| 63643-1 | Drug type used in your lifetime [AUDADIS-IV] |
| 63644-9 | Have you ever used any of these medicines or drugs [SSAGA II] |
| 63645-6 | How old were you when you first used this drug [AUDADIS-IV] |
| 63646-4 | During the past 30 days, on how many days did you use drugs [PhenX] |
| 63647-2 | Did you ever use marijuana at least 21 times in a single year [SSAGA II] |
| 63648-0 | Has there ever been a period of a month or more when a great deal of your time was spent using marijuana, getting marijuana, or getting over its effects [SSAGA II] |
| 63649-8 | Problem, related to marijuana use, that occurred for more than 24 hours to the point that it interfered with functioning or relationships [SSAGA II] |
| 63651-4 | Did you continue to use marijuana after you knew it caused this problem [SSAGA II] |
| 63652-2 | Have you often wanted to stop or cut down on marijuana [SSAGA II] |
| 63653-0 | Have you ever tried to stop or cut down on marijuana but found you couldn't [SSAGA II] |
| 63654-8 | Were you unable to stop or cut down on marijuana 3 or more times [SSAGA II] |
| 63655-5 | Have you often used marijuana more frequently or in larger amounts than you intended to [SSAGA II] |
| 63656-3 | Did you ever need larger amounts of marijuana to get an effect, or did you ever find that you could no longer get high on the amount you used to use [SSAGA II] |
| 63657-1 | When you stopped, cut down, or went without marijuana, did you ever experience any of these problems for most of the day for 2 days or longer [SSAGA II] |
| 63658-9 | Have you ever used marijuana to keep from having any of these problems or to make them go away [SSAGA II] |
| 63659-7 | Did using marijuana, to keep from having any of these problems, happen 3 or more times [SSAGA II] |
| 63660-5 | Did these problems, related to using marijuana, ever occur together [SSAGA II] |
| 63661-3 | Did giving up, or greatly reducing important activities while using marijuana happen 3 or more times or last for a month or longer [SSAGA II] |
| 63662-1 | Medicine or drug used to feel good or high, or to feel more active or alert [SSAGA II] |
| 63664-7 | How many times in your life have you used this medicine or drug [SSAGA II] |
| 63665-4 | Was there ever a period of a month or more when a great deal of your time was spent getting over this drug or its effects [SSAGA II] |
| 63666-2 | Have you often wanted to stop or cut down on this drug [SSAGA II] |
| 63667-0 | Have you ever tried to stop or cut down on this drug but found that you couldn't [SSAGA II] |
| 63668-8 | Were you unable to stop or cut down 3 or more times on this drug [SSAGA II] |
| 63669-6 | Did you ever need larger amounts of this drug to get an effect or find that you could no longer get high on the amount you used to use [SSAGA II] |
| 63670-4 | Have you ever given up or greatly reduced important activities like sports, work, or associating with friends or relatives while using this drug [SSAGA II] |
| 63671-2 | Drug type used steadily, for a month or more [SSAGA II] |
| 63672-0 | Did giving up or greatly reducing important activities while using this drug, happen 3 or more times or more or for a month or more [SSAGA II] |
| 63673-8 | Have you often used this drug, used steadily, more days or in larger amounts than you intended to [SSAGA II] |
| 63674-6 | Problem when you stopped, cut down, or went without drugs after using drugs steadily [SSAGA II] |
| 63675-3 | When you stopped, cut down, or went without drugs after using drugs steadily, did you ever experience this problem [SSAGA II] |
| 63676-1 | Was there ever a time, because of stopping, cutting down on, or going without this drug, after using it steadily, when 2 or more of these problems occurred together [SSAGA II] |
| 63677-9 | Have you ever used this drug to keep from having any of these problems or make them go away [SSAGA II] |
| 63678-7 | Did you have to use this drug to make problems go away 3 or more times [SSAGA II] |
| 63679-5 | Did using this drug cause you to have any other problems, like an overdose that required medical treatment [SSAGA II] |
| 63680-3 | Did an overdose of this drug that required medical treatment, happen 3 or more times [SSAGA II] |
| 63681-1 | Did using this drug cause you to have any other problems, like hepatitis [SSAGA II] |
| 63682-9 | Did you continue to use this drug knowing it caused hepatitis [SSAGA II] |
| 63683-7 | Did using this drug cause you to have any other serious health problems [SSAGA II] |
| 63684-5 | Did you continue to use this drug knowing it caused other serious health problems [SSAGA II] |
| 63685-2 | Has use of this drug ever caused you emotional or psychological problems for more than 24 hours to the point that it interfered with your functioning or relationships [SSAGA II] |
| 63686-0 | Did you continue to use drug after you knew it caused any of these emotional or psychological problems [SSAGA II] |
| 63687-8 | Which specific drug of this type did you use [SSAGA II] |
| 63688-6 | Emotional or psychological problem related to drug use [SSAGA II] |
| 63689-4 | Drug used in past 30 days [PhenX] |
| 63690-2 | Have you given up or greatly reduced important activities like sports, work, or associating with friends or relatives while using marijuana [SSAGA II] |
| 63691-0 | Problem when you stopped, cut down or went without marijuana for 2 days or longer [SSAGA II] |
| 63692-8 | What is type of dwelling [ICAS] |
| 63693-6 | Type of dwelling if other [ICAS] |
| 63694-4 | Is property actively used as a farm or ranch [NHEXAS] |
| 63695-1 | What is the approximate age of your building [MESA] |
| 63696-9 | What year was building built [LIBCSP] |
| 63697-7 | What month did you start living there [LIBCSP] |
| 63698-5 | What year did you start living there [LIBCSP] |
| 63699-3 | At what age did you start living there [NHEXAS] |
| 63700-9 | What month did you move from there [NHEXAS] |
| 63701-7 | What year did you move from there [NHEXAS] |
| 63702-5 | What age did you move from there [NHEXAS] |
| 63703-3 | How many years have or did you live there [NHEXAS] |
| 63704-1 | Is there an enclosed garage attached to this house or apartment [NHEXAS] |
| 63705-8 | Are automobiles, vans, trucks or other motor vehicles parked in this attached garage [NHEXAS] |
| 63706-6 | Are any gas powered devices stored in any room, basement, or attached garage in this house or apartment [NHEXAS] |
| 63707-4 | During the past 12 months, has there been water or dampness in your home from broken pipes, leaks, heavy rain, or floods [NSLAH] |
| 63708-2 | Does your home frequently have a mildew odor or musty smell [NSLAH] |
| 63709-0 | Is air conditioning, refrigeration, used to cool this house or apartment [NHEXAS] |
| 63710-8 | Which types of air conditioning units do you use [NHEXAS] |
| 63711-6 | During which month do you usually start using air conditioning to cool this house or apartment [NHEXAS] |
| 63712-4 | During which month do you usually stop using air conditioning [NHEXAS] |
| 63713-2 | Which fuels are used for heating this house or apartment [NHEXAS] |
| 63714-0 | Does this house or apartment have a central heating system with ducts that blow air into most rooms [NHEXAS] |
| 63715-7 | During which month do you usually start using heating devices [NHEXAS] |
| 63716-5 | During which month do you usually stop using heating devices [NHEXAS] |
| 63717-3 | In the last 12 months, did any dogs, cats or other small furry animals, such as a rabbit, guinea pig or hamster, live or spend time inside your home [NHANES] |
| 63718-1 | What kind of pet lived or spent time inside your home [NHANES] |
| 63719-9 | What was the primary source of drinking water at your home [Next-of-kin] |
| 63720-7 | What was the primary source of drinking water at your home if other [Next-of-kin] |
| 63721-5 | What was the depth of the private well [Next-of-kin] |
| 63722-3 | Was the private well cased [Next-of-kin] |
| 63725-6 | Residence [PEG] |
| 63726-4 | From what date did you live in the residence |
| 63727-2 | To what date did you live in the residence |
| 63728-0 | What is the residence address, street - crosstreets, city, state or landmark [PEG] |
| 63729-8 | Was this on a farm [PEG] |
| 63730-6 | What was your water supply [PEG] |
| 63731-4 | What was your water supply if other [PEG] |
| 63732-2 | Near fields or orchards [PEG] |
| 63733-0 | Did you live close to the center or margin of town [PEG] |
| 63734-8 | Were geocoordinates verified [PEG] |
| 63735-5 | How were the geocoordinates verified [PEG] |
| 63736-3 | Materials to which you were exposed in your work or daily life [ACSCP-II] |
| 63737-1 | In your work or daily life, were you regularly exposed to this material [ACSCP-II] |
| 63738-9 | How many years were you regularly exposed to this material [ACSCP-II] |
| 63739-7 | How many hours did you work last week at all jobs or businesses in the past week [NHANES] |
| 63740-5 | Do you usually work 35 hours or more per week in total at all jobs or businesses [NHANES] |
| 63741-3 | For whom did you work for at your main job or business [NHANES] |
| 63742-1 | What kind of business or industry is this [NHANES] |
| 63743-9 | What kind of work were you doing [NHANES] |
| 63744-7 | What were your most important activities on this job [NHANES] |
| 63745-4 | Which of the following best describes the hours you usually work at you main job or business [NHANES] |
| 63746-2 | About how long have you worked for your employer in your occupation [NHANES] |
| 63748-8 | What kind of work were you doing the longest [NHANES] |
| 63749-6 | What kind of business or industry did you work in for the longest period of time [NHANES] |
| 63750-4 | What were your most important activities on this job or business [NHANES] |
| 63751-2 | About how long did you work at that job or business |
| 63752-0 | Since the age 16, did you ever work for 6 months or more [NHANES] |
| 63753-8 | Job number [NHANES] |
| 63754-6 | What was the name of the company where you first or next worked, for 6 months or longer [NHANES] |
| 63755-3 | What was the job title of the first or next job you held at this company [NHANES] |
| 63756-1 | In what year did you start working at this job [NHANES] |
| 63757-9 | In what year did you stop working at this job [NHANES] |
| 63758-7 | What was the location of this company [Address] [NHANES] |
| 63759-5 | Was this a full-time or part-time job [NHANES] |
| 63760-3 | What did they make, or what service did they provide - what type of business was it [NHANES] |
| 63761-1 | What were your main activities or duties for this job [NHANES] |
| 63762-9 | What kinds of chemicals or materials did you handle in that job [NHANES] |
| 63763-7 | What kinds of tools and equipment did you use [NHANES] |
